<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/258803-phenylquinazoline-derivatives by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 04:22:55 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 258803:PHENYLQUINAZOLINE DERIVATIVES</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PHENYLQUINAZOLINE DERIVATIVES</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Novel phenylquinazoline derivatives of the formula I in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>-1 -<br>
Phenylquinazoline derivatives<br>
BACKGROUND OF THE INVENTION<br>
The invention was based on the object of finding novel compounds having<br>
valuable properties, in particular those which can be used for the prepara-<br>
tion of medicaments.<br>
The present invention relates to compounds in which the inhibition, regula-<br>
tion and/or modulation of HSP90 plays a role, furthermore to pharmaceuti-<br>
cal compositions which comprise these compounds, and to the use of the<br>
compounds for the treatment of diseases in which HSP90 plays a role.<br>
The correct folding and conformation of proteins in cells is ensured by<br>
molecular chaperones and is critical for the regulation of the equilibrium<br>
between protein synthesis and degradation. Chaperones are important for<br>
the regulation of many central functions of cells, such as, for example, cell<br>
proliferation and apoptosis (Jolly and Morimoto, 2000; Smith et al., 1998;<br>
Smith, 2001).<br>
Heat shock proteins (HSPs)<br>
The cells of a tissue react to external stress, such as, for example, heat,<br>
hypoxia, oxidative stress, or toxic substances, such as heavy metals or<br>
alcohols, with activation of a number of chaperones which are known<br>
under the term "heat shock proteins" (HSPs).<br>
The activation of HSPs protects the cell against damage initiated by such<br>
stress factors, accelerates the restoration of the physiological state and<br>
results in a stress-tolerant state of the cell.<br>
Besides this originally discovered protective mechanism promoted by<br>
HSPs against external stress, further important chaperone functions<br>
have also been described in the course of time for individual HSPs<br>
under normal stress-free conditions. Thus, various HSPs regulate, for<br><br>
-2-<br>
example, correct folding, intracellular localisation and function or regu-<br>
lated degradation of a number of biologically important proteins of cells.<br>
HSPs form a gene family with individual gene products whose cellular ex-<br>
pression, function and localisation differs in different cells. The naming and<br>
classification within the family is carried out on the basis of their molecular<br>
weight, for example HSP27, HSP70, and HSP90.<br>
Some human diseases are based on incorrect protein folding (see review,<br>
for example, Tytelletal., 2001; Smith etal., 1998). The development of<br>
therapies which engages in the mechanism of the chaperone-dependent<br>
protein folding could therefore be useful in such cases. For example, incor-<br>
rectly folded proteins result in aggregation of protein with neurodegenera-<br>
tive progression in the case of Alzheimer's disease, prion diseases or<br>
Huntington's syndrome. Incorrect protein folding may also result in loss of<br>
wild-type function, which can have the consequence of incorrectly regu-<br>
lated molecular and physiological function.<br>
HSPs are also ascribed great importance in tumour diseases. There are,<br>
for example, indications that the expression of certain HSPs correlates with<br>
the stage of progression of tumours (Martin et al., 2000; Conroy et al.,<br>
1996; Kawanishi et al., 1999; Jameel et al., 1992; Hoang et al., 2000;<br>
Lebeauetal., 1991).<br>
The fact that HSP90 plays a role in a number of central oncogenic signal-<br>
ling pathways in the cell and certain natural products having cancer-inhib-<br>
iting activity target HSP90 has led to the concept that inhibition of the func-<br>
tion of HSP90 would be sensible in the treatment of tumour diseases.<br>
An HSP90 inhibitor, 17- allylamino-17-demethoxygeldanamycin (17AAG),<br>
a derivative of geldanamycin, is currently undergoing clinical trials,<br>
HSP90<br>
HSP90 represents approximately 1-2% of the total cellular protein mass. It<br><br>
-3-<br>
is usually in the form of a dimer in the cell and is associated with a multipli-<br>
city of proteins, so-called co-chaperones (see, for example, Pratt, 1997).<br>
HSP90 is essential for the vitality of cells (Young et al., 2001) and plays a<br>
key role in the response to cellular stress by interaction with many proteins<br>
whose native folding has been modified by external stress, such as, for<br>
example, heat shock, in order to restore the original folding or to prevent<br>
aggregation of the proteins (Smith etal.,1998).<br>
There are also indications that HSP90 is of importance as buffer against<br>
the effects of mutations, presumably through correction of incorrect protein<br>
folding caused by the mutation (Rutherford and Lindquist, 1998).<br>
In addition, HSP90 also has a regulatory importance. Under physiological<br>
conditions, HSP90, together with its homologue in the endoplasmatic<br>
reticulum, GRP94, plays a role in the cell balance for ensuring the stability<br>
of the conformation and maturing of various client key proteins. These can<br>
be divided into three groups: receptors for steroid hormones, Ser/Thr or<br>
tyrosine kinases (for example ERBB2, RAF-1, CDK4 and LCK) and a col-<br>
lection of various proteins, such as, for example, mutated p53 or the cata-<br>
lytic subunit of telomerase hTERT. Each of these proteins takes on a key<br>
role in the regulation of physiological and biochemical processes of cells.<br>
The preserved HSP90 family in humans consists of four genes, cytosolic<br>
HSP90a, the inducible HSP90p isoform (Hickey et al., 1989), GRP94 in<br>
the endoplasmatic reticulum (Argon et al., 1999) and HSP75/TRAP1 in the<br>
mitochondrial matrix (Felts et al., 2000). It is assumed that all members of<br>
the family have a similar mode of action, but, depending on their localisa-<br>
tion in the cell, bind to different client proteins. For example, ERBB2 is a<br>
specific client protein of GRP94 (Argon et al., 1999), while the type 1<br>
receptor of tumour necrosis factor (TNFR1) or the retinoblastoma protein<br>
(Rb) have been found to be clients of TRAP1 (Song et al., 1995; Chen et<br>
al., 1996).<br>
HSP90 is involved in a number of complex interactions with a large num-<br>
ber of client proteins and regulatory proteins (Smith, 2001 ). Although pre-<br><br>
-4-<br>
cise molecular details have not yet been clarified, biochemical experiments<br>
and investigations with the aid of X-ray crystallography in recent years<br>
have increasingly been able to decipher details of the chaperone function<br>
of HSP90 (Prodromou et al., 1997; Stebbins et al., 1997). Accordingly,<br>
HSP90 is an ATP-dependent molecular chaperone (Prodromou et al,<br>
1997), with dimerisation being important for ATP hydrolysis. The binding of<br>
ATP results in the formation of a toroidal dimer structure, in which the two<br>
N-terminal domains come into close contact with one another and act as a<br>
switch in the conformation (Prodromou and Pearl, 2000).<br>
Known HSP90 inhibitors<br>
The first class of HSP90 inhibitors to be discovered were benzoquinone<br>
ansamycins with the compounds herbimycin A and geldanamycin. Origi-<br>
nally, the reversion of the malignant phenotype in fibroblasts which had<br>
been induced by transformation with the v-Src oncogene was detected<br>
with them (Uehara et al., 1985).<br>
Later, a strong antitumoural activity was demonstrated in vitro (Schulte et<br>
al., 1998) and in vivo in animal models (Supko et al., 1995).<br>
Immune precipitation and investigations on affinity matrices then showed<br>
that the principal mechanism of action of geldanamycin involves binding to<br>
HSP90 (Whitesell et al., 1994; Schulte and Neckers, 1998). In addition,<br>
X-ray crystallographic studies have shown that geldanamycin competes for<br>
the ATP binding site and inhibits the intrinsic ATPase activity of HSP90<br>
(Prodromou et al, 1997; Panaretou et al., 1998). This prevents the forma-<br>
tion of the multimeric HSP90 complex, with its property of functioning as<br>
chaperone for client proteins. As a consequence, client proteins are<br>
degraded via the ubiquitin-proteasome pathway.<br>
The geldanamycin derivative 17- allylamino-17-demethoxygeldanamycin<br>
(17AAG) showed an unchanged property in the inhibition of HSP90, the<br>
degradation of client proteins and antitumoural activity in cell cultures and<br><br>
-5-<br>
in xenograft tumour models (Schulte et al, 1998; Kelland et al, 1999), but<br>
had significantly lower liver cytotoxicity than geldanamycin (Page et all<br>
1997).17AAG is currently undergoing phase l/ll clinical trials.<br>
Radicicol, a macrocyclic antibiotic, likewise exhibited revision of the<br>
v-Src and v-Ha-Ras-induced malignant phenotype of fibroblasts (Kwon<br>
et all 1992; Zhao et al, 1995). Radicicol degrades a large number of<br>
signal proteins as a consequence of HSP90 inhibition (Schulte et al.,<br>
1998). X-ray crystallographic studies have shown that radicicol likewise<br>
binds to the N-terminal domain of HSP90 and inhibits the intrinsic<br>
ATPase activity (Roe et al., 1998).<br>
Antibiotics of the coumarine type, as is known, bind to the ATP binding<br>
site of the HSP90 homolog DNA gyrase in bacteria. The coumarine,<br>
Novobiocin, binds to the carboxy-terminal end of HSP90, i.e. to a differ-<br>
ent site in HSP90 than the benzoquinone-ansamycins and radicicol,<br>
which bind to the N-terminal end of HSP90 (Marcu et al., 2000b).<br>
The inhibition of HSP90 by novobiocin results in degradation of a large<br>
number of HSP90-dependent signal proteins (Marcu et al., 2000a).<br>
The degradation of signal proteins, for example ERBB2, was demon-<br>
strated using PU3, an HSP90 inhibitor derived from purines. PU3 causes<br>
cell cycle arrest and differentiation in breast cancer cell lines (Chiosis et<br>
al.,2001).<br>
HSP90 as therapeutic target<br>
Due to the participation of HSP90 in the regulation of a large number of<br>
signalling pathways which have crucial importance in the phenotype of a<br>
tumour, and the discovery that certain natural products exert their biologi-<br>
cal effect through inhibition of the activity of HSP90, HSP90 is currently<br><br>
-6-<br>
being tested as a novel target for the development of a tumour therapeutic<br>
agent (Neckers et al., 1999).<br>
The principal mechanism of action of geldanamycin, 17AAG, and radicicol<br>
includes the inhibition of the binding of ATP to the ATP binding site at the<br>
N-terminal end of the protein and the resultant inhibition of the intrinsic<br>
ATPase activity of HSP90 (see, for example, Prodromou et al., 1997;<br>
Stebbins et al., 1997; Panaretou et al., 1998). Inhibition of the ATPase ac-<br>
tivity of HSP90 prevents the recruitment of co-chaperones and favours the<br>
formation of an HSP90 heterocomplex, which causes client proteins to<br>
undergo degradation via the ubiquitin-proteasome pathway (see, for<br>
example, Neckers et al., 1999; Kelland et al., 1999). The treatment of<br>
tumour cells with HSP90 inhibitors results in selective degradation of im-<br>
portant proteins having fundamental importance for processes such as cell<br>
proliferation, regulation of the cell cycle and apoptosis. These processes<br>
are frequently deregulated in tumours (see, for example, Hostein et al.,<br>
2001).<br>
An attractive rationale for the development of an inhibitor of HSP90 is that<br>
a strong tumour-therapeutic action can be achieved by simultaneous deg-<br>
radation of a plurality of proteins which are associated with the trans-<br>
formed phenotype.<br>
In detail, the present invention relates to compounds which inhibit, regulate<br>
and/or modulate HSP90, to compositions which comprise these com-<br>
pounds, and to methods for the use thereof for the treatment of HSP90-<br>
induced diseases, such as tumour diseases, viral diseases, such as, for<br>
example, hepatitis B (Waxman, 2002); immune suppression in transplants<br>
(Bijlmakers, 2000 and Yorgin, 2000); inflammation-induced diseases<br>
(Bucci, 2000), such as rheumatoid arthritis, asthma, multiple sclerosis, type<br>
1 diabetes, lupus erythematosus, psoriasis and inflammatory bowel dis-<br>
ease; cystic fibrosis (Fuller, 2000); diseases associated with angiogenesis<br>
(Hur, 2002 and Kurebayashi, 2001 ), such as, for example, diabetic reti-<br><br>
-7-<br>
nopathy, haemangiomas, endometriosis and tumour angiogenesis; infec-<br>
tious diseases; autoimmune diseases; ischaemia; promotion of nerve re-<br>
generation (Rosen et al., WO 02/09696; Degranco et al., WO 99/51223;<br>
Gold, US 6,210,974 B1); fibrogenetic diseases, such as, for example,<br>
sclerorma, polymyositis, systemic lupus, cirrhosis of the liver, keloid forma-<br>
tion, interstitial nephritis and pulmonary fibrosis (Strehlow, WO 02/02123).<br>
The invention also relates to the use of the compounds according to the<br>
invention for the protection of normal cells against toxicity caused by<br>
chemotherapy, and to the use in diseases where incorrect protein folding<br>
or aggregation is a principal causal factor, such as, for example, scrapie,<br>
Creutzfeldt-Jakob disease, Huntington's or Alzheimer's (Sittler, Hum. Mol.<br>
Genet., 10, 1307, 2001; Tratzelt et al., Proc. Nat. Acad. Sci., 92, 2944,<br>
1995; Winklhofer et al., J. Biol. Chem., 276, 45160, 2001). WO 01/72779<br>
describes purine compounds and the use thereof for the treatment of<br>
GRP94 (homologue or paralogue of HSP90)-induced diseases, such as<br>
tumour diseases, where the cancerous tissue includes a sarcoma or carci-<br>
noma selected from the group consisting of fibrosarcoma, myxosarcoma,<br>
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angio-<br>
sarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelio-<br>
sarcoma, synovioma, mesothelioma, Ewing's tumour, leiosarcoma,<br>
rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,<br>
ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell<br>
carcinoma, adenocarcinoma, syringocarcinoma, sebaceous gland carci-<br>
noma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcino-<br>
mas, bone marrow carcinoma, bronchogenic carcinoma, renal cell carci-<br>
noma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma,<br>
embryonic carcinoma, Wilm's tumour, cervical cancer, testicular tumour,<br>
lung carcinoma, small-cell lung carcinoma, bladder carcinoma, epithelial<br>
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,<br>
ependymoma, pinealoma, haemangioblastoma, acoustic neuroma, oligo-<br>
dendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma,<br><br>
-8-<br>
leukaemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulin-<br>
aemia and heavy chain disease.<br>
A. Kamal et al. in Trends in Molecular Medicine, Vol. 10 No. 6 June 2004,<br>
describe therapeutic and diagnostic applications of HSP90 activation, inter<br>
alia for the treatment of diseases of the central nervous system and of<br>
cardiovascular diseases.<br>
The identification of small compounds which specifically inhibit, regulate<br>
and/or modulate HSP90 is therefore desirable and an aim of the present<br>
invention.<br>
It has been found that the compounds of the formula I and salts thereof<br>
have very valuable pharmacological properties while being well tolerated.<br>
In particular, they exhibit HSP90-inhibiting properties.<br>
The present invention therefore relates to compounds of the formula I as<br>
medicaments and/or medicament active ingredients in the treatment<br>
and/or prophylaxis of the said diseases and to the use of compounds of<br>
the formula I for the preparation of a pharmaceutical for the treatment<br>
and/or prophylaxis of the said diseases and also to a process for the treat-<br>
ment of the said diseases which comprises the administration of one or<br>
more compounds of the formula I to a patient in need of such an admini-<br>
stration.<br>
The host or patient may belong to any mammal species, for example a<br>
primate species, particularly humans; rodents, including mice, rats and<br>
hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of<br>
interest for experimental investigations, where they provide a model for the<br>
treatment of a human disease.<br><br>
-9-<br>
PRIOR ART<br>
WO 2005/00300 A1 describes triazole derivatives as HSP90 inhibitors.<br>
WO 00/53169 describes HSP90 inhibition with coumarine or a coumarine<br>
derivative.<br>
WO 03/041643 A2 discloses HSP90-inhibiting zearaianol derivatives.<br>
HSP90-inhibiting pyrazole derivatives which are substituted by an aromatic<br>
radical in the 3- or 5-position are disclosed in WO 2004/050087 A1 and<br>
WO 2004/056782 A1.<br>
WO 03/055860 A1 describes 3,4-diarylpyrazoles as HSP90 inhibitors.<br>
Purine derivatives having HSP90-inhibiting properties are disclosed in<br>
WO 02/36075 A2.<br>
WO 01/72779 describes purine compounds and the use thereof for the<br>
treatment of GRP94 (homologue or paralogue of HSP90)-induced dis-<br>
eases, such as tumour diseases, where the cancerous tissue includes a<br>
sarcoma or carcinoma selected from the group consisting of fibrosarcoma,<br>
myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chor-<br>
doma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymph-<br>
angioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumour, leio-<br>
sarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast<br>
cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal<br>
cell carcinoma, adenocarcinoma, syringocarcinoma, sebaceous gland car-<br>
cinoma, papillary carcinoma, papillary adenocarcinomas, cystadeno-<br>
carcinomas, bone marrow carcinoma, bronchogenic carcinoma, renal cell<br>
carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma,<br>
embryonic carcinoma, Wilm's tumour, cervical cancer, testicular tumour,<br>
lung carcinoma, small-cell lung carcinoma, bladder carcinoma, epithelial<br>
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,<br>
ependymoma, pinealoma, haemangioblastoma, acoustic neuroma, oligo-<br><br>
-10-<br>
dendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma,<br>
leukaemia, lymphoma, multiple myeloma, Waldenstrom's macroglobuli-<br>
naemia and heavy chain disease.<br>
WO 01/72779 furthermore discloses the use of the compounds mentioned<br>
therein for the treatment of viral diseases, where the viral pathogen is<br>
selected from the group consisting of hepatitis type A, hepatitis type B,<br>
hepatitis type C, influenza, varicella, adenovirus, herpes simplex type I<br>
(HSV-I), herpes simplex type II (HSV-II), cattle plague, rhinovirus, echo-<br>
virus, rotavirus, respiratory syncytial virus (RSV), papillomavirus, papova-<br>
virus, cytomegalovirus, echinovirus, arbovirus, huntavirus, Coxsackie virus,<br>
mumps virus, measles virus, rubella virus, polio virus, human immuno-<br>
deficiency virus type I (HIV-I) and human immunodeficiency virus type II<br>
(HIV-II).<br>
WO 01/72779 furthermore describes the use of the compounds mentioned<br>
therein for GRP94 modulation, where the modulated biological GRP94<br>
activity causes an immune reaction in an individual, protein transport from<br>
the endoplasmatic reticulum, recovery from hypoxic/anoxic stress, recov-<br>
ery from malnutrition, recovery from heat stress, or combinations thereof,<br>
and/or where the disorder is a type of cancer, an infectious disease, a dis-<br>
order associated with disrupted protein transport from the endoplasmatic<br>
reticulum, a disorder associated with ischaemia/reperfusion, or combina-<br>
tions thereof, where the disorder associated with ischaemia/reperfusion is<br>
a consequence of cardiac arrest, asystolia and delayed ventricular arrhyth-<br>
mia, heart operation, cardiopulmonary bypass operation, organ transplant,<br>
spinal cord trauma, head trauma, stroke, thromboembolic stroke, haemor-<br>
rhagic stroke, cerebral vasospasm, hypotonia, hypoglycaemia, status epi-<br>
lepticus, an epileptic fit, anxiety, schizophrenia, a neurodegenerative dis-<br>
order, Alzheimer's disease, Huntington's disease, amyotrophic lateral<br>
sclerosis (ALS) or neonatal stress.<br><br>
-11 -<br>
Finally, WO 01/72779 describes the use of an effective amount of a<br>
GRP94 protein modulator for the preparation of a medicament for chang-<br>
ing a subsequent cellular reaction to an ischaemic state in a tissue site in<br>
an individual, by treatment of the cells at the tissue site with the GRP94<br>
protein modulator in order that the GRP94 activity in cells is increased to<br>
such an extent that a subsequent cellular reaction to an ischaemic state is<br>
changed, where the subsequent ischaemic condition is preferably the con-<br>
sequence of cardiac arrest, asystolia and delayed ventricular arrhythmia,<br>
heart operation, cardiopulmonary bypass operation, organ transplant, spi-<br>
nal cord trauma, head trauma, stroke, thromboembolic stroke, haemor-<br>
rhagic stroke, cerebral vasospasm, hypotonia, hypoglycaemia, status epi-<br>
lepticus, an epileptic fit, anxiety, schizophrenia, a neurodegenerative dis-<br>
order, Alzheimer's disease, Huntington's disease, amyotrophic lateral scle-<br>
rosis (ALS) or neonatal stress, or where the tissue site is the donor tissue<br>
for a transplant.<br>
Further literature:<br>
Argon Y and Simen BB. 1999 "Grp94, an ER chaperone with protein and<br>
peptide binding properties", Semin. Cell Dev. Biol., Vol. 10, pp. 495-505.<br>
Bijlmakers M-JJE, Marsh M. 2000 "Hsp90 is essential for the synthesis and<br>
subsequent membrane association, but not the maintenance, of the Src-<br>
kinase p56lck", Mol. Biol. Cell, Vol. 11(5;, pp. 1585-1595.<br>
Bucci M; Roviezzo F; Cicala C; Sessa WC, Cirino G. 2000 "Geldanamycin,<br>
an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction<br>
has anti-inflammatory effects and interacts with glucocorticoid receptor in<br>
vivo", Brit. J. Pharmacol., Vol. 131(1), pp. 13-16.<br>
Carreras CW, Schirmer A, Zhong Z, Santi VS. 2003 "Filter binding assay<br>
for the geldanamycin-heat shock protein 90 interaction", Analytical<br>
Biochem., Vol. 317, pp 40-46.<br><br>
-12-<br>
Chen C-F, Chen Y, Dai KD, Chen P-L, Riley DJ and Lee W-H. 1996 "A<br>
new member of the hsp90 family of molecular chaperones interacts with<br>
the retinoblastoma protein during mitosis and after heat shock", Mol. Cell.<br>
Biol., Vol. 16, pp. 4691-4699.<br>
Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lozenzino<br>
L and Rosen N. 2001 "A small molecule designed to bind to the adenine<br>
nucleotide pocket of HSP90 causes Her2 degradation and the growth<br>
arrest and differentiation of breast cancer cells", Chem. Biol., Vol. 8,<br>
pp. 289-299.<br>
Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N 2002 "Development of a<br>
purine-scaffold novel class of HSP90 binders that inhibit the proliferation of<br>
cancer cells and induce the degradation of her2 tyrosine kinase". Bio-<br>
organic Med. Chem., Vol. 10, pp 3555-3564.<br>
Conroy SE and Latchman DS. 1996 "Do heat shock proteins have a role in<br>
breast cancer?", Brit. J. Cancer, Vol. 74, pp. 717-721.<br>
Felts SJ, Owen BAL, Nguyen P, Trepel J, Donner DB and Toft DO. 2000<br>
"The HSP90-related protein TRAP1 is a mitochondrial protein with distinct<br>
functional properties", J. Biol. Chem., Vol. 5, pp. 3305-331 2.<br>
Fuller W, Cuthbert AW. 2000 "Post-translational disruption of the delta<br>
F508 cystic fibrosis transmembrane conductance regulator (CFTR)-mole-<br>
cular Chaperone complex with geldanamycin stabilises delta F508 CFTR<br>
in the rabbit reticulocyte lysate", J. Biol. Chem., Vol. 275(48), pp. 37462-<br>
37468.<br><br>
-13-<br>
Hickey E, Brandon SE, Smale G, Lloyd D and Weber LA. 1999 "Sequence<br>
and regulation of a gene encoding a human 89-kilodalton heat shock pro-<br>
tein", Mol. Cell. Biol., Vol. 9, pp. 2615-2626.<br>
Hoang AT, Huang J, Rudra-Gonguly N, Zheng J, Powell WC, Rabindron<br>
SK, Wu C and Roy-Burman P. 2000 "A novel association between the<br>
human heat shock transcription factor 1 (HSF1) and prostate adenocarci-<br>
noma, Am. J. Pathol., Vol. 156, pp. 857-864.<br>
Hostein I, Robertson D, Di Stefano F, Workman P and Clarke PA. 2001<br>
"Inhibition of signal transduction by the HSP90 inhibitor 17-allylamino-<br>
1 7-demethoxygeldanamycin results in cytostasis and apoptosis", Cancer<br>
Res., Vol. 61, pp. 4003-4009.<br>
Hur E, Kim H-H, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee<br>
M-0, Park H. 2002 "Reduction of hypoxia-induced transcription through the<br>
repression of hypoxia-inducible factor-1a/aryl hydrocarbon receptor<br>
nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibi-<br>
tor radicicol", Mol. Pharmacol., Vol. 62(5), pp. 975-982.<br>
Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC and<br>
LuqmaniYA. 1992 "Clinical<br>
Jolly C and Morimoto Rl. 2000 "Role of the heat shock response and<br>
molecular chaperones in oncogenesis and cell death", J. Natl. Cancer<br>
Inst., Vol. 92, pp. 1564-1572.<br>
Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsujinata T,<br>
Shamma A and Monden M. 1999 "Prognostic significance of heat shock<br>
proteins 27 and 70 in patients with squamous cell carcinoma of the<br>
esophagus", Cancer, Vol. 85, pp. 1649-1657.<br><br>
-14-<br>
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M,<br>
Murrer BA, and Harrap KR. 1993 "Preclinical antitumour evaluation of bis-<br>
acetalo-amino-dichloro-cyclohexylamine platinum (IV): an orally active<br>
platinum drug", Cancer Research, Vol. 53, pp. 2581 - 2586.<br>
Kelland LR, Sharp SY, Rogers PM, Myers TG and Workman P. 1999<br>
"DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,<br>
17-demethoxygeldanamycin, an inhibitor of heat shock protein 90", J.<br>
Natl. Cancer Inst, Vol. 91, pp. 1940-1949.<br>
Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo, H. 2001<br>
"A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible<br>
factor-1a and vascular endothelial growth factor, angiogenesis and growth<br>
of human breast cancer xenografts", Jap. J. Cancer Res.,Vol. 92( 12),<br>
1342-1351.<br>
Kwon HJ, Yoshida M, Abe K, Horinouchi S and Bepple T. 1992 "Radicicol,<br>
an agent inducing the reversal of transformed phentoype of src-trans-<br>
formed fibroblasts, Biosci., Biotechnol., Biochem., Vol. 56, pp. 538-539.<br>
Lebeau J, Le Cholony C, Prosperi MT and Goubin G. 1991 "Constitutive<br>
overexpression of 89 kDa heat shock protein gene in the HBL100 mam-<br>
mary cell line converted to a tumorigenic phenotype by the EJE24 Harvey-<br>
ras oncogene", Oncogene, Vol. 6, pp. 1125-1132.<br>
Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers L. 2000a "The<br>
heat shock protein 90 antagonist novobiocin interacts with a previously<br>
unrecognised ATP-binding domain in the carboxyl terminus of the chaper-<br>
one", J. Biol. Chem., Vol. 275, pp. 37181-37186.<br><br>
-15-<br>
Marcu MG, Schulte TW and Neckers L. 2000b "Novobiocin and related<br>
coumarins and depletion of heat shock protein 90-dependent signaling<br>
proteins", J. Natl. Cancer Inst., Vol. 92, pp. 242-248.<br>
Martin KJ, Kritzman BM, Price LM, Koh B, Kwan CP, Zhang X, MacKay A,<br>
O'Hare MJ, Kaelin CM, Mutter GL, Pardee AB and Sager R. 2000 "Linking<br>
gene expression patterns to therapeutic groups in breast cancer", Cancer<br>
Res., Vol. 60, pp. 2232-2238.<br>
Neckers L, Schulte TW and Momnaaugh E. 1999 "Geldanamycin as a<br>
potential anti-cancer agent: its molecular target and biochemical activ-<br>
ity", Invest. New Druqs, Vol. 17, pp. 361-373.<br>
Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J,<br>
Smith A and Rodman L. 1997 "Comparison of geldanamycin (NSC-<br>
122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in<br>
rats", Proc. Am. Assoc. Cancer Res., Vol. 38, pp. 308.<br>
Panaretou B, Prodromou C, Roe SM, OBrien R, Ladbury JE, Piper PW<br>
and Pearl LH. 1998 "ATP binding and hydrolysis are essential to the<br>
function of the HSP90 molecular chaperone in vivo", EMBO J., Vol. 17,<br>
pp. 4829-4836.<br>
Pratt WB. 1997 "The role of the HSP90-based chaperone system in<br>
signal transduction by nuclear receptors and receptors signalling via<br>
MAP kinase", Annu. Rev. Pharmacol. Toxicol., Vol. 37, pp. 297-326.<br><br>
-16-<br>
Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH.<br>
1997 "Identification and structural characterisation of the ATP/ADP-binding<br>
site in the HSP90 molecular chaperone", Cell, Vol. 90, pp. 65-75.<br>
Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE,<br>
Roe SM, Piper PW and Pearl LH. 2000 "The ATPase cycle of HSP90<br>
drives a molecular "clamp" via transient dimerisation of the N-terminal<br>
domains", EMBO J., Vol. 19, pp. 4383-4392.<br>
Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW and Pearl LH.<br>
1999 "Structural basis for inhibition of the HSP90 molecular chaperone by<br>
the antitumour antibiotics radicicol and geldanamycin", J. Med. Chem., Vol.<br>
42, pp. 260-266.<br>
Rutherford SL and Lindquist S. 1998 "HSP90 as a capacitor for morpholo-<br>
gical evolution. Nature, Vol. 396, pp. 336-342.<br>
Schulte TW, Akinaga S, Murakata T, Agatsuma T, Sugimoto S, Nakano H,<br>
Lee YS, Simen BB, Argon Y, Felts S, Toft DO, Neckers LM and Sharma<br>
SV. 1999 "Interaction of radicicol with members of the heat shock protein<br>
90 family of molecular chaperones", Mol. Endocrinoloqy, Vol. 13, pp. 1435-<br>
1448.<br>
Schulte TW, Akinaga S, Soga S, Sullivan W, Sensgard B, Toft D and<br>
Neckers LM. 1998 "Antibiotic radicicol binds to the N-terminal domain of<br>
HSP90 and shares important biologic activities with geldanamcyin", Cell<br>
Stress and Chaperones, Vol. 3, pp. 100-108.<br>
Schulte TW and Neckers LM. 1998 "The benzoquinone ansamycin 17-<br>
allylamino-17-demethoxygeldanamcyin binds to HSP90 and shares<br>
important biologic activities with geldanamycin", Cancer Chemother.<br>
Pharmacol., Vol. 42, pp. 273-279.<br><br>
-17-<br>
Smith DF. 2001 "Chaperones in signal transduction", in: Molecular chaper-<br>
ones in the cell (P Lund, ed.; Oxford University Press, Oxford and NY),<br>
pp. 165-178.<br>
Smith DF, Whitesell L and Katsanis E. 1998 "Molecular chaperones:<br>
Biology and prospects for pharmacological intervention", Pharmacological<br>
Reviews, Vol. 50, pp. 493-513.<br>
Song HY, Dunbar JD, Zhang YX, Guo D and Donner DB. 1995 "Identifica-<br>
tion of a protein with homology to hsp90 that binds the type 1 tumour<br>
necrosis factor receptor", J. Biol. Chem., Vol. 270, pp. 3574-3581.<br>
Stebbins CE, Russo A, Schneider C, Rosen N, Hartl FU and Pavletich NP.<br>
1997 "Crystal structure of an HSP90-geldanamcyin complex: targeting of a<br>
protein chaperone by an antitumor agent", Cell, Vol. 89, pp. 239-250.<br>
Supko JG, Hickman RL, Grever MR and Malspeis L. 1995 "Preclinical<br>
pharmacologic evaluation of geldanamycin as an antitumour agent",<br>
Cancer Chemother. Pharmacol., Vol. 36, pp. 305-315.<br>
Tytell M and Hooper PL. 2001 "Heat shock proteins: new keys to the<br>
development of cytoprotective therapies", Emerging Therapeutic Tarqets,<br>
Vol. 5, pp. 267-287.<br>
Uehara U, Hori M, Takeuchi T and Umezawa H. 1986 "Phenotypic<br>
change from transformed to normal induced by benzoquinoid ansa-<br>
mycins accompanies inactivation of p60src in rat kidney cells infected<br>
with Rous sarcoma virus", Mol. Cell. Biol., Vol. 6, pp. 21 98-2206.<br><br>
-18-<br>
Waxman, Lloyd H. Inhibiting hepatitis C virus processing and replication.<br>
(Merck &amp; Co., Inc., USA). PCT Int. Appl. (2002), WO 0207761<br>
Whitesell L, Mimnaugh EG, De Costa B, Myers CE and Neckers LM. 1994<br>
"Inhibition of heat shock protein HSP90-pp60v~src heteroprotein complex<br>
formation by benzoquinone ansamycins: essential role for stress proteins<br>
in oncogenic transformation", Proc. Natl. Acad. Sci. USA., Vol. 91, pp.<br>
8324-8328.<br>
Yorgin et al. 2000 "Effects of geldanamycin, a heat-shock protein 90-bind-<br>
ing agent, on T cell function and T cell nonreceptor protein tyrosine<br>
kinases", J. Immunol., Vol. 164(6), pp. 2915-2923.<br>
Young JC, Moarefi I and Hartl FU. 2001 "HSP90: a specialised but essen-<br>
tial protein-folding tool", J. Cell. Biol., Vol. 154, pp. 267-273.<br>
Zhao JF, Nakano H and Sharma S. 1995 "Suppression of RAS and MOS<br>
transformation by radicicol", Oncogene, Vol. 11, pp. 161 -173.<br>
SUMMARY OF THE INVENTION<br>
The invention relates to compounds of the formula<br><br>
in which<br><br>
-19-<br>
R1	denotes Hal, OH, OA, SH, SA, H or A,<br>
R2, R3	each, independently of one another, denote -0-(X)s-Q,<br>
-S-(X)S-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q, -CONA-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NH(CO)0-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, -S02NA-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 + H, or<br>
ifR3 = H,thenR2*H,<br>
R4, R5	each, independently of one another, denote H, Hal, CN, NO2,<br>
A, OH, OA, SH, SA, (CH2)nCOOH, (CH2)nCOOA,<br>
O(CH2)0CONH2, CONHA, CONAA', NH2, NHA, NAA',<br>
NHCOOA, NHCO(CH2)nNH2, NHCONHA, SOA, S02A,<br>
S02NH2, S02NHA, S02NAA' or 0(CH2)0Het1,<br>
two adjacent radicals selected from the group R1, R2, R3<br>
together also denote methylenedioxy or ethylenedioxy,<br>
A, A'	each, independently of one another, denote unbranched or<br>
branched alkyl having 1-10 C atoms, in which 1-5 H atoms<br>
may be replaced by F, CI and/or Br,<br>
Alk or cyclic alkyl having 3-7 C atoms,<br>
A and A' together also denote an alkylene chain having 2, 3, 4, 5 or 6<br>
C atoms, in which one or two CH2 groups may be replaced by<br>
O, S, SO, S02, NH, NA and/or N-COOA,<br>
Alk	denotes alkenyl having 2-6 C atoms,<br>
X	denotes unbranched or branched C1-C10 alkylene or C2-C10<br>
alkenylene, each of which is unsubstituted or mono-, di-, tri-<br>
or tetrasubstituted by A, OA, OH, SH, SA, Hal, N02, CN, Ar,<br>
OAr, COOH, COOA, CHO, C(=0)A, C(=0)Ar, S02A, C0NH2,<br>
SO2NH2, CONHA, CONAA', S02NHA, S02NAA', NH2l NHA,<br>
NAA', OCONH2, OCONHA, OCONAA', NHCOA, NHCOOA,<br>
NACOOA, NHSO2OA, NAS02OA, NHCONH2, NACONH2,<br>
NHCONHA, NACONHA, NHCONAA', NACONAA' and/or =0<br>
and in which one, two or three C groups may be replaced by<br><br>
-20-<br>
O, S, SO, S02, NHCO, NACO, CONH, CONA, S02NH,<br>
S02NA, NHSO2, NASO2 and/or by NH groups,<br>
Q	denotes H, Carb, Ar or Het,<br>
Carb	denotes cycloalkyl having 3-7 C atoms or cycloalkenyl having<br>
3-7 C atoms, each of which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, OA, OH, SH, SA, Hal, N02,<br>
CN, (CH2)nAr\ (CH2)nCOOH, (CH2)nCOOA, CHO, COA,<br>
S02A, CONH2, S02NH2, CONHA, CONAA', S02NHA,<br>
S02NAA\ NH2, NHA, NAA*, OCONH2, OCONHA, OCONAA',<br>
NHCOA, NHCOOA, NACOOA, NHS02OA, NAS02OA,<br>
NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA'<br>
or NACONAA',<br>
Ar	denotes phenyl, naphthyl or biphenyl, each of which is<br>
unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by<br>
A, OA, OH, SH, SA, Hal, N02, CN, (CH2)nAr*, (CH2)nCOOH,<br>
(CH2)nCOOA, CHO, COA, S02A, CONH2, S02NH2l CONHA,<br>
CONAA', S02NHA, S02NAA\ NH2, NHA, NAA', OCONH2,<br>
OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA,<br>
NHSO2OA, NASO2OA, NHCONH2, NACONH2, NHCONHA,<br>
NACONHA, NHCONAA' or NACONAA',<br>
Ar'	denotes phenyl, naphthyl or biphenyl, each of which is<br>
unsubstituted or mono-, di- or trisubstituted by A, OA, OH,<br>
SH, SA, Hal, N02, CN, (CH2)nphenyl, (CH2)nCOOH,<br>
(CH2)nCOOA, CHO, COA, S02A, CONH2, S02NH2, CONHA,<br>
CONAA', SO2NHA, S02NAA', NH2, NHA, NAA', OCONH2,<br>
OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA,<br>
NHSO2OA, NAS02OA, NHCONH2, NACONH2, NHCONHA,<br>
NACONHA, NHCONAA' or NACONAA',<br>
Het	denotes a mono- or bicyclic saturated, unsaturated or aro-<br>
matic heterocycle having 1 to 4 N, O and/or S atoms, which<br>
may be mono-, di- or trisubstituted by A, OA, OH, SH, SA,<br>
Hal, N02, CN, (CH2)nAr\ (CH2)nCOOH, (CH2)nCOOA, CHO,<br><br>
-21 -<br>
COA, S02A, CONH2, S02NH2, CONHA, CONAA', S02NHA,<br>
S02NAA', NH2, NHA, NAA', OCONH2, OCONHA, OCONAA',<br>
NHCOA, NHCOOA, NACOOA, NHS02OA, NAS02OA,<br>
NHCONH2, NACONH2, NHCONHA, NACONHA, NHCONAA',<br>
NACONAA', S02A, =S, =NH, =NA and/or =0 (carbonyl oxy-<br>
gen),<br>
Het1	denotes a monocyclic saturated, unsaturated or aromatic<br>
heterocycle having 1 to 2 N and/or 0 atoms, which may be<br>
mono- or disubstituted by A, OA, OH, Hal and/or =0<br>
(carbonyl oxygen),<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1, 2, 3 or 4,<br>
o	denotes 1, 2 or 3,<br>
s	denotes 0 or 1,<br>
and pharmaceutical usable derivatives, salts, solvates, tautomers and<br>
stereoisomers thereof, including mixtures thereof in all ratios.<br>
The invention relates to the compounds of the formula I and salts thereof<br>
and to a process for the preparation of compounds of the formula I<br>
according to Claims 1-15 and pharmaceutical usable derivatives, sol-<br>
vates, salts, tautomers and stereoisomers thereof, characterised in that<br>
one or more radical(s) R1, R2, R3, R4 and/or R5 in a compound of the for-<br>
mula I is (are) converted into one or more radical(s) R1, R2, R3, R4 and/or<br>
R5,<br>
by alkylating or acylating a hydroxyl and/or amino group group,<br>
and/or a base or acid of the formula I is converted into one of its salts.<br>
The invention also relates to the hydrates and solvates of these com-<br>
pounds, solvates of the compounds are taken to mean adductions of inert<br>
solvent molecules onto the compounds which form owing to their mutual<br><br>
-22-<br>
attractive force, solvates are, for example, mono- or dihydrates or alcoho-<br>
lates.<br>
The compounds of the formula I according to the invention may also exist<br>
in tautomeric forms. Formula I encompasses all these tautomeric forms.<br>
Pharmaceutically usable derivatives are taken to mean, for example, the<br>
salts of the compounds according to the invention and also so-called pro-<br>
drug compounds.<br>
Prodrug derivatives are taken to mean compounds of the formula I which<br>
have been modified with, for example, alkyl or acyl groups, sugars or oligo-<br>
peptides and which are rapidly cleaved in the organism to give the effec-<br>
tive compounds according to the invention.<br>
These also include biodegradable polymer derivatives of the compounds<br>
according to the invention, as described, for example, in Int. J. Pharm.<br>
115,61-67(1995).<br>
The expression "effective amount" means the amount of a medicament or<br>
pharmaceutical active ingredient that causes a biological or medical<br>
response which is sought or desired, for example, by a researcher or<br>
physician in a tissue, system, animal or human.<br>
In addition, the expression "therapeutically effective amount" means an<br>
amount which, compared with a corresponding subject who has not<br>
received this amount, has the following consequence:<br>
improved healing treatment, healing, prevention or elimination of a dis-<br>
ease, a disease picture, a disease state, a complaint, a disorder or of side<br>
effects or also the reduction in the progress of a disease, a complaint or a<br>
disorder.<br>
The term "therapeutically effective amount" also encompasses the<br>
amounts which are effective for increasing normal physiological function.<br><br>
-23-<br>
The invention also relates to mixtures of the compounds of the formula I<br>
according to the invention, for example mixtures of two diastereomers, for<br>
example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.<br>
These are particularly preferably mixtures of stereoisomeric compounds.<br>
For all radicals which occur more than once, their meanings are independ-<br>
ent of one another.<br>
Above and below, the radicals and parameters R1, R2, R3, R4 and R5 have<br>
the meanings indicated for the formula I, unless expressly indicated other-<br>
wise.<br>
A or A' preferably denotes alkyl, is unbranched (linear) or branched, and<br>
has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A or A' particularly preferably<br>
denotes denotes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl<br>
or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or<br>
2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or4-methylpentyl, 1,1-,<br>
1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-<br>
methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2-or 1,2,2-trimethylpropyl.<br>
A or A' very particularly preferably denotes alkyl having 1,2,3, 4, 5 or 6 C<br>
atoms, preferably ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-<br>
butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl,<br>
furthermore also fluoromethyl, difluoromethyl or bromomethyl.<br>
A or A' also denotes cycloalkyl. Cycloalkyl preferably denotes cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.<br>
A or A' also denotes Alk. Alk denotes alkenyl having 2-6 C atoms, such as,<br>
for example, vinyl or propenyl.<br>
Cycloalkylalkylene denotes, for example, cyclohexylmethyl, cyclohexyl-<br>
ethyl, cyclopentylmethyl or cyclopentylethyl.<br>
C1-C10 alkylene preferably denotes methylene, ethylene, propylene, buty-<br>
lene, pentylene, hexylene, heptylene, octylene, nonylene or decylene, iso-<br>
propylene, isobutylene, sec-butylene, 1-, 2- or 3-methylbutylene, 1,1-, 1,2-<br><br>
-24-<br>
or 2,2-dimethylpropylene, 1-ethylpropylene, 1-, 2-, 3- or 4-methylpenty-<br>
lene, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutylene, 1 - or 2-ethyl-<br>
butylene, 1-ethyl-1-methylpropylene, 1-ethyl-2-methylpropylene, 1,1,2-or<br>
1,2,2-trimethylpropylene, particularly preferably methylene, ethylene,<br>
propylene, butylene, pentylene or hexylene.<br>
Aikenylene denotes a hydrocarbon chain having 2-10 C atoms, having 2<br>
free valences and containing at least one double bond.<br>
Ac denotes acetyl, Bzl denotes benzyl, Ms denotes -S02CH3.<br>
Y denotes OH; OA, preferably methoxy; SH; SA, preferably methylsulfanyl;<br>
amino; NHA, preferably methylamino; NAA', preferably dimethylamino or<br>
diethylamino.<br>
R1 preferably denotes OH or OA, such as, for example, methoxy; further-<br>
more H or Hal.<br>
R2, R3 preferably each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q, -NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 * H, or<br>
if R3 = H, then R2 * H.<br>
R4, R5 preferably each, independently of one another, denote H, Hal, A,<br>
OH, OA, 0(CH2)0CONH2, NHCO(CH2)nNH2 or 0(CH2)0Het1.<br>
R4 preferably denotes H, Hal, OH or OA.<br>
R5 preferably denotes H, Hal, A, OH, OA, O(CH2)0CONH2,<br>
NHCO(CH2)nNH2 or 0(CH2)0Het1.<br>
X preferably denotes unbranched or branched C1-C10 alkylene which is<br>
unsubstituted or mono- or disubstituted by OA, OH, COOH, COOA,<br>
CONH2, NH2, NHA and/or NAA' and in which one, two or three C groups<br>
may be replaced by O, NHCO, CONH and/or by NH groups.<br><br>
-25-<br>
X preferably denotes unbranched or branched C1-C10 alkylene which is<br>
unsubstituted or mono- or disubstituted by OA, OH, COOH, CN, COOA,<br>
CONH2, NH2, NHA and/or NAA' and in which one, two or three C groups<br>
may be replaced by O, NHCO, CONH and/or by NH groups.<br>
Ar denotes, for example, phenyl, 0-, m- or p-tolyl, 0-, m- or p-ethylphenyl,<br>
o-, m- or p-propylphenyl, 0-, m- or p-isopropylphenyl, 0-, m- or p-tert-butyl-<br>
phenyl, 0-, m- or p-hydroxyphenyl, 0-, m- or p-nitrophenyl, 0-, m- or p-<br>
aminophenyl, 0-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methyl-<br>
aminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxy-<br>
phenyl, o-, m- or p-ethoxyphenyl, 0-, m- or p-ethoxycarbonylphenyl, 0-, m-<br>
or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)-<br>
phenyl, 0-, m- or p-(N-ethylamino)phenyl, 0-, m- or p-(N,N-diethylamino)-<br>
phenyl, o-, m- or p-fluorophenyl, 0-, m- or p-bromophenyl, o-, m- or p-<br>
chlorophenyl, 0-, m- or p-(methy!sulfonamido)phenyl, o-, m- or p-(methyl-<br>
sulfonyl)phenyl, o-, m- or p-cyanophenyl, 0-, m- or p-ureidophenyl, o-, m-<br>
or p-formylphenyl, 0-, m- or p-acetylphenyl, 0-, m- or p-aminosulfonyl-<br>
phenyl, o-, m- or p-carboxyphenyl, o-, m- or p-carboxymethylphenyl, 0-, m-<br>
or p-carboxymethoxyphenyl, further preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or<br>
3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-,<br>
2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or<br>
3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-<br>
3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl,<br>
2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-<br>
diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-<br>
trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-di-<br>
chloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl,<br>
2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-meth-<br>
oxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-<br>
amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-<br>
chlorophenyl.<br><br>
-26-<br>
Ar preferably denotes, for example, phenyl which is unsubstituted or<br>
mono-, di-, tri-, tetra- or pentasubstituted by A, Hal, OA and/or<br>
(CH2)nCOOH and/or (CH2)nCOOA.<br>
Ar particularly preferably denotes phenyl, o-, m- or p-tolyl, o-, m- or p-ethyl-<br>
phenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or<br>
p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, o-, m- or p-fluoro-<br>
phenyl, o-, m- or p-chlorophenyl, o-, m- or p-methoxycarbonylphenyl, o-,<br>
m- or p-carboxyphenyl.<br>
Ar' preferably denotes, for example, phenyl which is unsubstituted or<br>
mono-, di- or trisubstituted by Hal.<br>
Irrespective of further substitutions, Het denotes, for example, 2- or 3-furyl,<br>
2-	or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or<br>
5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl,<br>
3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further-<br>
more preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1-<br>
or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-<br>
thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl,<br>
3-	or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-iso-<br>
indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indazolyl, 1-,<br>
3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-,<br><br>
6-	or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or<br>
7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-,<br>
7-	or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or<br>
8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-,<br>
5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, further preferably 1,3-benzodioxol-5-<br>
yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benz-<br>
oxadiazol-5-yl.<br>
The heterocyclic radicals may also be partially or fully hydrogenated.<br>
Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl,<br>
2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or-3-furyl, 1,3-dioxolan-4-yl,<br><br>
-27-<br>
tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-di-<br>
hydro-1-, -2-, -3-, -4- or-5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2-<br>
or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-,<br>
-3-or-4-pyrazolyl, 1,4-dihydro-1-, -2-, -3-or-4-pyridyl, 1,2,3,4-tetrahydro-<br>
1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-mor-<br>
pholinyl, tetrahydro-2-, -3- or-4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or<br>
-5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimi-<br>
dinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7-<br>
or-8-quinolyl, 1,2,3,4-tetrahydro-1-,-2-,-3-, -4-, -5-, -6-, -7-or-8-isoquinolyl,<br>
2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, further preferably<br>
2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxy-<br>
phenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-<br>
dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-<br>
dihydro-2H-1,5-benzodioxepin-6- or-7-yl, furthermore preferably 2,3-di-<br>
hydrobenzofuranyl or 2,3-dihydro-2-oxofuranyl.<br>
Het preferably denotes a mono- or bicyclic saturated, unsaturated or aro-<br>
matic heterocycle having 1 to 4 N, O and/or S atoms, which may be mono-<br>
, di- or trisubstituted by A, OH, OA and/or Hal.<br>
Het particularly preferably denotes a monocyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be<br>
mono-, di- or trisubstituted by A, (CH2)nAr' and/or (CH2)nCOOA.<br>
In a further embodiment, Het preferably denotes a mono-or bicyclic aro-<br>
matic heterocycle having 1 to 2 N, O and/or S atoms, which may be mono-<br>
, di- or trisubstituted by A, OH, OA and/or Hal, where A preferably denotes<br>
methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl or trifluoromethyl.<br>
In a further embodiment, Het particularly preferably denotes unsubstituted<br>
or mono-OH-substituted 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-,<br>
2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or<br><br>
-28-<br>
5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl,<br>
2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-<br>
yl, 1,2,4-triazoM-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl,<br>
1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or<br>
-5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-,<br>
5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 2-, 3-,<br>
4-, 5-, 6- or 7-indazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or<br>
7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzo-<br>
thiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxa-<br>
diazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquino-<br>
lyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or<br>
6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, further prefera-<br>
bly 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or<br>
-5-yl or 2,1,3-benzoxadiazol-5-yl.<br>
Het very extraordinarily preferably denotes unsubstituted or mono-OH-<br>
substituted imidazolyl, pyridyl, pyrimidinyl, indolyl, benzimidazolyl or inda-<br>
zolyl.<br>
Het1 preferably denotes a monocyclic saturated heterocycle having 1 to 2<br>
N and/or O atoms, such as, for example, piperazinyl, piperidinyl, pyrroli-<br>
dinyl or morpholinyl, each of which may be mono- or disubstituted by A<br>
and/or =0 (carbonyl oxygen). Het1 very particularly preferably denotes<br>
4-A-piperazinyl, where A denotes alkyl having 1-6 C atoms.<br>
The compounds of the formula I may have one or more chiral centres and<br>
therefore occur in various stereoisomeric forms. The formula I encom-<br>
passes all these forms.<br>
Accordingly, the invention relates, in particular, to the compounds of the<br>
formula I in which at least one of the said radicals has one of the preferred<br>
meanings indicated above. Some preferred groups of compounds may be<br><br>
-29-<br>
expressed by the following sub-formulae la to II, which conform to the for-<br>
mula I and in which the radicals not designated in greater detail have the<br>
meaning indicated for the formula I, but in which<br>
in la	R1	denotes Hal, OH, OA or H;<br>
in lb	R2, R3 each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then RH, or<br>
if R3 = H, then R2 * H;<br>
in Ic	R4, R5 each, independently of one another, denote H, Hal, A,<br>
OH, OA, 0(CH2)0CONH2, NHCO(CH2)nNH2 or<br>
0(CH2)0Het1;<br>
in Id	R4 denotes H, Hal, OH or OA,<br>
R5	denotes H, Hal, A, OH, OA, O(CH2)0CONH2,<br>
NHCO(CH2)nNH2 or 0(CH2)0Het1;<br>
in le	X	denotes unbranched or branched CrCio alkylene which<br>
is unsubstituted or mono- or disubstituted by OA, OH,<br>
COOH, COOA, CONH2, NH2, NHA and/or NAA' and in<br>
which one, two or three C groups may be replaced by<br>
O, NHCO, CONH and/or by NH groups;<br>
in If	Q	denotes H, Ar or Het;<br>
in Ig	Ar denotes phenyl which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, Hal, OA and/or<br>
(CH2)nCOOH and/or (CH2)nCOOA;<br><br>
-30-<br>
in Ih	Het denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms,<br>
which may be mono-, di- or trisubstituted by A, OH, OA<br>
and/or Hal;<br>
in li	Het denotes a mono- or bicyclic aromatic heterocycle having<br>
1	to 4 N, O and/or S atoms, which may be mono-, di- or<br>
trisubstituted by A, OH, OA and/or Hal;<br>
in Ij	Het1 denotes a monocyclic saturated heterocycle having 1 to<br>
2	N and/or O atoms, which may be mono- or disubstitu-<br>
ted by A and/or =0 (carbonyl oxygen);<br>
in Ik	A	denotes unbranched or branched alkyl having 1-6 C<br>
atoms, in which 1-5 H atoms may be replaced by F<br>
and/or CI;<br>
in II	R1	denotes Hal, OH, OA or H,<br>
R2, R3 each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 * H, or<br>
if R3 = H, then R2 * H,<br>
R4, R5 each, independently of one another, denote H, Hal, A,<br>
OH, OA, 0(CH2)oCONH2, NHCO(CH2)nNH2 or<br>
O(CH2)0Het1,<br>
X	denotes unbranched or branched CrCio alkylene which<br>
is unsubstituted or mono- or disubstituted by OA, OH,<br>
COOH, COOA, CONH2, NH2, NHA and/or NAA' and in<br><br>
-31 -<br>
which one, two or three C groups may be replaced by<br>
O, NHCO, CONH and/or by NH groups,<br>
Q	denotes H, Ar or Het,<br>
Ar	denotes phenyl which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, Hal, OA and/or<br>
(CH2)nCOOH and/or (CH2)nCOOA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms,<br>
which may be mono-, di- or trisubstituted by A, OH, OA<br>
and/or Hal,<br>
Het1 denotes a monocyclic saturated heterocycle having 1 to<br>
2 N and/or O atoms, which may be mono- or disubstitu-<br>
ted by A and/or =0 (carbonyl oxygen),<br>
A, A' each, independently of one another, denote unbranched<br>
or branched alkyl having 1-6 C atoms, in which 1-5 H<br>
atoms may be replaced by F and/or CI,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1, 2, 3 or 4,<br>
o	denotes 1, 2 or 3,<br>
s	denotes 0 or 1;<br>
in Im	R1	denotes Hal, OH, OA or H,<br>
R2, R3 each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 * H, or<br>
if R3 = H, then R21 H,<br>
R4 denotes H, Hal, OH or OA,<br>
R5	denotes H, Hal, A, OH, OA, 0(CH2)0CONH2,<br>
NHCO(CH2)nNH2 or 0(CH2)0Het1,<br><br>
-32-<br>
X	denotes unbranched or branched Ci-C) alkylene which<br>
is unsubstituted or mono- or disubstituted by OA, OH,<br>
COOH, COOA, CONH2 and/or NH2 and in which one,<br>
two or three C groups may be replaced by O, NHCO,<br>
CONH and/or by NH groups,<br>
Q	denotes H, Ar or Het,<br>
Ar denotes phenyl which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, Hal, OA and/or<br>
(CH2)nCOOH and/or (CH2)nCOOA,<br>
Het denotes a mono- or bicyclic aromatic heterocycle having<br>
1	to 4 N, O and/or S atoms, which may be mono-, di- or<br>
trisubstituted by A, OH, OA and/or Hal,<br>
Het1 denotes a monocyclic saturated heterocycle having 1 to<br>
2	N and/or O atoms, which may be mono- or disubstitu-<br>
ted by A and/or =0 (carbonyl oxygen),<br>
A	denotes unbranched or branched alkyl having 1-6 C<br>
atoms, in which 1-5 H atoms may be replaced by F<br>
and/or CI,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1, 2, 3 or 4,<br>
0	denotes 1, 2 or 3,<br>
s	denotes 0 or 1;<br>
and pharmaceutically usable derivatives, solvates, salts, tautomers and<br>
stereoisomers thereof, including mixtures thereof in all ratios.<br>
The compounds according to the invention and also the starting materials<br>
for their preparation are, in addition, prepared by methods known per se,<br>
as described in the literature (for example in the standard works, such as<br>
Houben-Weyl, Methoden der organischen Chemie [Methods of Organic<br>
Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction<br>
conditions which are known and suitable for the said reactions. Use may<br><br>
-33-<br>
also be made here of variants known per se which are not mentioned here<br>
in greater detail.<br>
If desired, the starting materials can also be formed in situ by not isolating<br>
them from the reaction mixture, but instead immediately converting them<br>
further into the compounds according to the invention.<br>
The starting compounds are generally known. If they are novel, however,<br>
they can be prepared by methods known per se.<br>
The reactions are carried out by methods which are known to the person<br>
skilled in the art.<br>
The reactions are carried out in a suitable inert solvent.<br>
Examples of suitable inert solvents are hydrocarbons, such as hexane,<br>
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,<br>
such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chlo-<br>
roform or dichloromethane; alcohols, such as methanol, ethanol, isopropa-<br>
nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether,<br>
diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as<br>
ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl<br>
ether (diglyme); ketones, such as acetone or butanone; amides, such as<br>
acetamide, dimethylacetamide or dimethylformamide (DMF); nitrites, such<br>
as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon di-<br>
sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-<br>
pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-<br>
tate, or mixtures of the said solvents.<br>
Depending on the conditions used, the reaction times are between a few<br>
minutes and 14 days, the reaction temperature is between about -30 and<br>
140, normally between -10 and 130, in particular between about 30 and<br>
about 125.<br><br>
-34-<br>
Free amino groups are acylated, for example, in a conventional manner<br>
using an acid chloride or anhydride or alkylated using an unsubstituted or<br>
substituted alkyl halide, advantageously in an inert solvent, such as di-<br>
chloromethane or THF, and/or in the presence of a base, such as triethyl-<br>
amine or pyridine, at temperatures between -60 and +30.<br>
Pharmaceutical salts and other forms<br>
The said compounds according to the invention can be used in their final<br>
non-salt form. On the other hand, the present invention also encompasses<br>
the use of these compounds in the form of their pharmaceutical accept-<br>
able salts, which can be derived from various organic and inorganic acids<br>
and bases by procedures known in the art. Pharmaceutically acceptable<br>
salt forms of the compounds of the formula I are for the most part prepared<br>
by conventional methods. If the compound of the formula I contains a car-<br>
boxyl group, one of its suitable salts can be formed by reacting the com-<br>
pound with a suitable base to give the corresponding base-addition salt.<br>
Such bases are, for example, alkali metal hydroxides, including potassium<br>
hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal<br>
hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal<br>
alkoxides, for example potassium ethoxide and sodium propoxide; and<br>
various organic bases, such as piperidine, diethanolamine and N-methyl-<br>
glutamine. The aluminium salts of the compounds of the formula I are like-<br>
wise included. In the case of certain compounds of the formula I, acid-<br>
addition salts can be formed by treating these compounds with pharma-<br>
ceutically acceptable organic and inorganic acids, for example hydrogen<br>
halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide,<br>
other mineral acids and corresponding salts thereof, such as sulfate,<br>
nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such<br>
as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other<br>
organic acids and corresponding salts thereof, such as acetate, trifluoro-<br>
acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascor-<br><br>
-35-<br>
bate and the like. Accordingly, pharmaceutically acceptable acid-addition<br>
salts of the compounds of the formula I include the following: acetate, adi-<br>
pate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate),<br>
bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate,<br>
caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, diglu-<br>
conate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethane-<br>
sulfonate, fumarate, galacterate (from mucic acid), galacturonate, gluco-<br>
heptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate,<br>
hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydro-<br>
bromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-<br>
butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate,<br>
metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos-<br>
phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo-<br>
ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate,<br>
phosphonate, phthalate, but this does not represent a restriction.<br>
Furthermore, the base salts of the compounds according to the invention<br>
include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium,<br>
magnesium, manganese(lll), manganese(ll), potassium, sodium and zinc<br>
salts, but this is not intended to represent a restriction. Of the above-men-<br>
tioned salts, preference is given to ammonium; the alkali metal salts so-<br>
dium and potassium, and the alkaline earth metal salts calcium and mag-<br>
nesium. Salts of the compounds of the formula I which are derived from<br>
pharmaceutically acceptable organic non-toxic bases include salts of pri-<br>
mary, secondary and tertiary amines, substituted amines, also including<br>
naturally occurring substituted amines, cyclic amines, and basic ion ex-<br>
changer resins, for example arginine, betaine, caffeine, chloroprocaine,<br>
choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine,<br>
diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-<br>
ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperi-<br>
dine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine,<br>
lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, pipera-<br><br>
-36-<br>
zine, piperidine, polyamine resins, procaine, purines, theobromine, tri-<br>
ethanolamine, triethylamine, trimethylamine, tripropylamine and tris-<br>
(hydroxymethyl)methylamine (tromethamine), but this is not intended to<br>
represent a restriction.<br>
Compounds of the present invention which contain basic nitrogen-contain-<br>
ing groups can be quaternised using agents such as (C1-C4)alky! halides,<br>
for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and<br>
iodide; di(CrC4)alkyl sulfates, for example dimethyl, diethyl and diamyl<br>
sulfate; (Ci0-Ci8)alkyl halides, for example decyl, dodecyl, lauryl, myristyl<br>
and stearyl chloride, bromide and iodide; and aryl(CrC4)alkyl halides, for<br>
example benzyl chloride and phenethyl bromide. Both water- and oil-solu-<br>
ble compounds according to the invention can be prepared using such<br>
salts.<br>
The above-mentioned pharmaceutical salts which are preferred include<br>
acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisucci-<br>
nate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, me-<br>
glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-<br>
rate, sulfate, subsalicylate, tartrate, thiomalate, tosylate and trometh-<br>
amine, but this is not intended to represent a restriction.<br>
The acid-addition salts of basic compounds of the formula I are prepared<br>
by bringing the free base form into contact with a sufficient amount of the<br>
desired acid, causing the formation of the salt in a conventional manner.<br>
The free base can be regenerated by bringing the salt form into contact<br>
with a base and isolating the free base in a conventional manner. The free<br>
base forms differ in a certain respect from the corresponding salt forms<br>
thereof with respect to certain physical properties, such as solubility in<br>
polar solvents; for the purposes of the invention, however, the salts other-<br>
wise correspond to the respective free base forms thereof.<br><br>
-37-<br>
As mentioned, the pharmaceutically acceptable base-addition salts of the<br>
compounds of the formula I are formed with metals or amines, such as<br>
alkali metals and alkaline earth metals or organic amines. Preferred metals<br>
are sodium, potassium, magnesium and calcium. Preferred organic<br>
amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, di-<br>
ethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.<br>
The base-addition salts of acidic compounds according to the invention are<br>
prepared by bringing the free acid form into contact with a sufficient<br>
amount of the desired base, causing the formation of the salt in a conven-<br>
tional manner. The free acid can be regenerated by bringing the salt form<br>
into contact with an acid and isolating the free acid in a conventional man-<br>
ner. The free acid forms differ in a certain respect from the corresponding<br>
salt forms thereof with respect to certain physical properties, such as solu-<br>
bility in polar solvents; for the purposes of the invention, however, the salts<br>
otherwise correspond to the respective free acid forms thereof.<br>
If a compound according to the invention contains more than one group<br>
which is capable of forming pharmaceutically acceptable salts of this type,<br>
the invention also encompasses multiple salts. Typical multiple salt forms<br>
include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-<br>
phosphate, disodium and trihydrochloride, but this is not intended to repre-<br>
sent a restriction.<br>
With regard to that stated above, it can be seen that the expression<br>
"pharmaceutically acceptable salt" in the present connection is taken to<br>
mean an active ingredient which comprises a compound of the formula I in<br>
the form of one of its salts, in particular if this salt form imparts improved<br>
pharmacokinetic properties on the active ingredient compared with the free<br>
form of the active ingredient or any other salt form of the active ingredient<br>
used earlier. The pharmaceutically acceptable salt form of the active in-<br>
gredient can also provide this active ingredient for the first time with a de-<br><br>
-38-<br>
sired pharmacokinetic property which it did not have earlier and can even<br>
have a positive influence on the pharmacodynamics of this active ingredi-<br>
ent with respect to its therapeutic efficacy in the body.<br>
Compounds of the formula I according to the invention may be chiral owing<br>
to their molecular structure and may accordingly occur in various enantio-<br>
meric forms. They can therefore exist in racemic or in optically active form.<br>
Since the pharmaceutical activity of the racemates or stereoisomers of the<br>
compounds of the formula I may differ, it may be desirable to use the en-<br>
antiomers. In these cases, the end product or even the intermediates can<br>
be separated into enantiomeric compounds by chemical or physical meas-<br>
ures known to the person skilled in the art or even employed as such in the<br>
synthesis.<br>
In the case of racemic amines, diastereomers are formed from the mixture<br>
by reaction with an optically active resolving agent. Examples of suitable<br>
resolving agents are optically active acids, such as the R and S forms of<br>
tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid,<br>
malic acid, lactic acid, suitably N-protected amino acids (for example N-<br>
benzoylproline or N-benzenesulfonylproline), or the various optically active<br>
camphorsulfonic acids. Also advantageous is chromatographic enantiomer<br>
resolution with the aid of an optically active resolving agent (for example<br>
dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of<br>
carbohydrates or chirally derivatised methacrylate polymers immobilised<br>
on silica gel). Suitable eluents for this purpose are aqueous or alcoholic<br>
solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile,<br>
for example in the ratio 82:15:3.<br>
The invention furthermore relates to the use of the compounds and/or<br>
physiologically acceptable salts thereof for the preparation of a medica-<br>
ment (pharmaceutical composition), in particular by non-chemical meth-<br>
ods. They can be converted into a suitable dosage form here together with<br><br>
-39-<br>
at least one solid, liquid and/or semi-liquid excipient or adjuvant and, if de-<br>
sired, in combination with one or more further active ingredients.<br>
The invention furthermore relates to medicaments comprising at least one<br>
compound of the formula I and/or pharmaceutical usable derivatives, sol-<br>
vates and stereoisomers thereof, including mixtures thereof in all ratios,<br>
and optionally excipients and/or adjuvants.<br>
Pharmaceutical formulations can be administered in the form of dosage<br>
units which comprise a predetermined amount of active ingredient per<br>
dosage unit. Such a unit can comprise, for example, 0.1 mg to 3 g, pref-<br>
erably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a com-<br>
pound according to the invention, depending on the disease condition<br>
treated, the method of administration and the age, weight and condition of<br>
the patient, or pharmaceutical formulations can be administered in the<br>
form of dosage units which comprise a predetermined amount of active<br>
ingredient per dosage unit. Preferred dosage unit formulations are those<br>
which comprise a daily dose or part-dose, as indicated above, or a corres-<br>
ponding fraction thereof of an active ingredient. Furthermore, pharmaceu-<br>
tical formulations of this type can be prepared using a process which is<br>
generally known in the pharmaceutical art.<br>
Pharmaceutical formulations can be adapted for administration via any<br>
desired suitable method, for example by oral (including buccal or sublin-<br>
gual), rectal, nasal, topical (including buccal, sublingual or transdermal),<br>
vaginal or parenteral (including subcutaneous, intramuscular, intravenous<br>
or intradermal) methods. Such formulations can be prepared using all<br>
processes known in the pharmaceutical art by, for example, combining the<br>
active ingredient with the excipient(s) or adjuvant(s).<br>
Pharmaceutical formulations adapted for oral administration can be admin-<br>
istered as separate units, such as, for example, capsules or tablets; pow-<br><br>
-40-<br>
ders or granules; solutions or suspensions in aqueous or non-aqueous liq-<br>
uids; edible foams or foam foods; or oil-in-water liquid emulsions or water-<br>
in-oil liquid emulsions.<br>
Thus, for example, in the case of oral administration in the form of a tablet<br>
or capsule, the active-ingredient component can be combined with an oral,<br>
non-toxic and pharmaceutically acceptable inert excipient, such as, for<br>
example, ethanol, glycerol, water and the like. Powders are prepared by<br>
comminuting the compound to a suitable fine size and mixing it with a<br>
pharmaceutical excipient comminuted in a similar manner, such as, for<br>
example, an edible carbohydrate, such as, for example, starch or mannitol.<br>
A flavour, preservative, dispersant and dye may likewise be present.<br>
Capsules are produced by preparing a powder mixture as described above<br>
and filling shaped gelatine shells therewith. Glidants and lubricants, such<br>
as, for example, highly disperse silicic acid, talc, magnesium stearate, cal-<br>
cium stearate or polyethylene glycol in solid form, can be added to the<br>
powder mixture before the filling operation. A disintegrant or solubiliser,<br>
such as, for example, agar-agar, calcium carbonate or sodium carbonate,<br>
may likewise be added in order to improve the availability of the medica-<br>
ment after the capsule has been taken.<br>
In addition, if desired or necessary, suitable binders, lubricants and disin-<br>
tegrants as well as dyes can likewise be incorporated into the mixture.<br>
Suitable binders include starch, gelatine, natural sugars, such as, for ex-<br>
ample, glucose or beta-lactose, sweeteners made from maize, natural and<br>
synthetic rubber, such as, for example, acacia, tragacanth or sodium algi-<br>
nate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The<br>
lubricants used in these dosage forms include sodium oleate, sodium<br>
stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium<br>
chloride and the like. The disintegrants include, without being restricted<br>
thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like.<br><br>
-41 -<br>
The tablets are formulated by, for example, preparing a powder mixture,<br>
granulating or depressing the mixture, adding a lubricant and a disinteg-<br>
rant and pressing the entire mixture to give tablets. A powder mixture is<br>
prepared by mixing the compound comminuted in a suitable manner with a<br>
diluent or a base, as described above, and optionally with a binder, such<br>
as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-<br>
pyrrolidone, a dissolution retardant, such as, for example, paraffin, an ab-<br>
sorption accelerator, such as, for example, a quaternary salt, and/or an<br>
absorbent, such as, for example, bentonite, kaolin or dicalcium phosphate.<br>
The powder mixture can be granulated by wetting it with a binder, such as,<br>
for example, syrup, starch paste, acadia mucilage or solutions of cellulose<br>
or polymer materials and pressing it through a sieve. As an alternative to<br>
granulation, the powder mixture can be run through a tableting machine,<br>
giving lumps of non-uniform shape which are broken up to form granules.<br>
The granules can be lubricated by addition of stearic acid, a stearate salt,<br>
talc or mineral oil in order to prevent sticking to the tablet casting moulds.<br>
The lubricated mixture is then pressed to give tablets. The compounds<br>
according to the invention can also be combined with a free-flowing inert<br>
excipient and then pressed directly to give tablets without carrying out the<br>
granulation or drypressing steps. A transparent or opaque protective layer<br>
consisting of a shellac sealing layer, a layer of sugar or polymer material<br>
and a gloss layer of wax may be present. Dyes can be added to these<br>
coatings in order to be able to differentiate between different dosage units.<br>
Oral liquids, such as, for example, solution, syrups and elixirs, can be pre-<br>
pared in the form of dosage units so that a given quantity comprises a pre-<br>
specified amount of the compounds. Syrups can be prepared by dissolving<br>
the compound in an aqueous solution with a suitable flavour, while elixirs<br>
are prepared using a non-toxic alcoholic vehicle. Suspensions can be for-<br>
mulated by dispersion of the compound in a non-toxic vehicle. Solubilisers<br>
and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and<br>
polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as,<br><br>
-42-<br>
for example, peppermint oil or natural sweeteners or saccharin, or other<br>
artificial sweeteners and the like, can likewise be added.<br>
The dosage unit formulations for oral administration can, if desired, be en-<br>
capsulated in microcapsules. The formulation can also be prepared in<br>
such a way that the release is extended or retarded, such as, for example,<br>
by coating or embedding of particulate material in polymers, wax and the<br>
like.<br>
The compounds of the formula I and salts, solvates and physiologically<br>
functional derivatives thereof can also be administered in the form of lipo-<br>
some delivery systems, such as, for example, small unilamellar vesicles,<br>
large unilamellar vesicles and multilamellar vesicles. Liposomes can be<br>
formed from various phospholipids, such as, for example, cholesterol,<br>
stearylamine or phosphatidylcholines.<br>
The compounds of the formula I and the salts, solvates and physiologically<br>
functional derivatives thereof can also be delivered using monoclonal anti-<br>
bodies as individual carriers to which the compound molecules are cou-<br>
pled. The compounds can also be coupled to soluble polymers as targeted<br>
medicament carriers. Such polymers may encompass polyvinylpyrrolidone,<br>
pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxy-<br>
ethylaspartamidophenol or polyethylene oxide polylysine, substituted by<br>
palmitoyl radicals. The compounds may furthermore be coupled to a class<br>
of biodegradable polymers which are suitable for achieving controlled<br>
release of a medicament, for example polylactic acid, poly-epsilon-capro-<br>
lactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, poly-<br>
dihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block<br>
copolymers of hydrogels.<br>
Pharmaceutical formulations adapted for transdermal administration can<br>
be administered as independent plasters for extended, close contact with<br><br>
-43-<br>
the epidermis of the recipient. Thus, for example, the active ingredient can<br>
be delivered from the plaster by iontophoresis, as described in general<br>
terms in Pharmaceutical Research, 3(6), 318 (1986).<br>
Pharmaceutical compounds adapted for topical administration can be for-<br>
mulated as ointments, creams, suspensions, lotions, powders, solutions,<br>
pastes, gels, sprays, aerosols or oils.<br>
For the treatment of the eye or other external tissue, for example mouth<br>
and skin, the formulations are preferably applied as topical ointment or<br>
cream. In the case of formulation to give an ointment, the active ingredient<br>
can be employed either with a paraffinic or a water-miscible cream base.<br>
Alternatively, the active ingredient can be formulated to give a cream with<br>
an oil-in-water cream base or a water-in-oil base.<br>
Pharmaceutical formulations adapted for topical application to the eye in-<br>
clude eye drops, in which the active ingredient is dissolved or suspended<br>
in a suitable carrier, in particular an aqueous solvent.<br>
Pharmaceutical formulations adapted for topical application in the mouth<br>
encompass lozenges, pastilles and mouthwashes.<br>
Pharmaceutical formulations adapted for rectal administration can be ad-<br>
ministered in the form of suppositories or enemas.<br>
Pharmaceutical formulations adapted for nasal administration in which the<br>
carrier substance is a solid comprise a coarse powder having a particle<br>
size, for example, in the range 20-500 microns, which is administered in<br>
the manner in which snuff is taken, i.e. by rapid inhalation via the nasal<br>
passages from a container containing the powder held close to the nose.<br>
Suitable formulations for administration as nasal spray or nose drops with<br><br>
-44-<br>
a liquid as carrier substance encompass active-ingredient solutions in<br>
water or oil.<br>
Pharmaceutical formulations adapted for administration by inhalation en-<br>
compass finely particulate dusts or mists, which can be generated by vari-<br>
ous types of pressurised dispensers with aerosols, nebulisers or insuffla-<br>
tors.<br>
Pharmaceutical formulations adapted for vaginal administration can be<br>
administered as pessaries, tampons, creams, gels, pastes, foams or spray<br>
formulations.<br>
Pharmaceutical formulations adapted for parenteral administration include<br>
aqueous and non-aqueous sterile injection solutions comprising antioxi-<br>
dants, buffers, bacteriostatics and solutes, by means of which the formula-<br>
tion is rendered isotonic with the blood of the recipient to be treated; and<br>
aqueous and non-aqueous sterile suspensions, which may comprise sus-<br>
pension media and thickeners. The formulations can be administered in<br>
single-dose or multidose containers, for example sealed ampoules and<br>
vials, and stored in freeze-dried (lyophilised) state, so that only the addition<br>
of the sterile carrier liquid, for example water for injection purposes, imme-<br>
diately before use is necessary.<br>
Injection solutions and suspensions prepared in accordance with the rec-<br>
ipe can be prepared from sterile powders, granules and tablets.<br>
It goes without saying that, in addition to the above particularly mentioned<br>
constituents, the formulations may also comprise other agents usual in the<br>
art with respect to the particular type of formulation; thus, for example,<br>
formulations which are suitable for oral administration may comprise fla-<br>
vours.<br><br>
-45-<br>
A therapeutically effective amount of a compound of the formula I depends<br>
on a number of factors, including, for example, the age and weight of the<br>
human or animal, the precise disease condition which requires treatment,<br>
and its severity, the nature of the formulation and the method of admini-<br>
stration, and is ultimately determined by the treating doctor or vet. How-<br>
ever, an effective amount of a compound according to the invention is<br>
generally in the range from 0.1 to 100 mg/kg of body weight of the recipi-<br>
ent (mammal) per day and particularly typically in the range from 1 to<br>
10 mg/kg of body weight per day. Thus, the actual amount per day for an<br>
adult mammal weighing 70 kg is usually between 70 and 700 mg, where<br>
this amount can be administered as an individual dose per day or usually<br>
in a series of part-doses (such as, for example, two, three, four, five or six)<br>
per day, so that the total daily dose is the same. An effective amount of a<br>
salt or solvate or of a physiologically functional derivative thereof can be<br>
determined as the fraction of the effective amount of the compound of the<br>
formula I perse. It can be assumed that similar doses are suitable for the<br>
treatment of other conditions mentioned above.<br>
The invention furthermore relates to medicaments comprising at least one<br>
compound of the formula I and/or pharmaceutically usable derivatives, sol-<br>
vates and stereoisomers thereof, including mixtures thereof in all ratios,<br>
and at least one further medicament active ingredient.<br>
Further medicament active ingredients are preferably chemotherapeutic<br>
agents, in particular those which inhibit angiogenesis and thus inhibit the<br>
growth and spread of tumour cells; preference is given here to VEGF<br>
receptor inhibitors, including robozymes and antisense which are directed<br>
to VEGF receptors, and angiostatin and endostatin.<br>
Examples of antineoplastic agents which can be used in combination with<br>
the compounds according to the invention generally include alkylating<br>
agents, antimetabolites; epidophyllotoxin; an antineoplastic enzyme; a<br><br>
-46-<br>
topoisomerase inhibitor; procarbazin; mitoxantron or platinum coordination<br>
complexes.<br>
Antineoplastic agents are preferably selected from the following classes:<br>
anthracyclins, vinca medicaments, mitomycins, bleomycins, cytotoxic<br>
nucleosides, epothilones, discormolides, pteridines, diynenes and podo-<br>
phyllotoxins.<br>
Particular preference is given in the said classes to, for example, carmino-<br>
mycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-<br>
methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 5-fluorodeoxy-<br>
uridine monophosphate, cytarabine, 5-azacytidine, thioguanine, azathio-<br>
prine, adenosine, pentostatin, erythrohydroxynonyladenine, cladribine,<br>
6-mercaptopurine, gemcitabine, cytosinarabinoside, podophyllotoxin or<br>
podophyllotoxin derivatives, such as, for example, etoposide, etoposide<br>
phosphate or teniposide, melphalan, vinblastine, vinorelbine, vincristine,<br>
leurosidine, vindesine, leurosine, docetaxel and paclitaxel. Other preferred<br>
antineoplastic agents are selected from the group discormolide, epothilone<br>
D, estramustine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide,<br>
bleomycin, gemcitabine, ifosamide, melphalan, hexamethylmelamine, thio-<br>
tepa, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin,<br>
CPT-11, topotecan, arabinosylcytosine, bicalutamide, flutamide, leuprolide,<br>
pyridobenzoindole derivatives, interferons and interleukins.<br>
Further medicament active ingredients are preferably antibiotics. Preferred<br>
antibiotics are selected from the group<br>
dactinomycin, daunorubicin, idarubicin, epirubicin, mitoxantrone, bleo-<br>
mycin, plicamycin, mitomycin.<br>
Further medicament active ingredients are preferably enzyme inhibitors.<br>
Preferred enzyme inhibitors are selected from the group<br>
of the histone deacetylation inhibitors (for example suberoylanilide hydrox-<br><br>
-47-<br>
amic acid [SAHA]) and the tyrosine kinase inhibitors (for example ZD 1839<br>
[Iressa]).<br>
Further medicament active ingredients are preferably nuclear export in-<br>
hibitors. Nuclear export inhibitors prevent the output of biopolymers (for<br>
example RNA) from the cell nucleus. Preferred nuclear export inhibitors<br>
are selected from the group callystatin, leptomycin B, ratjadone.<br>
Further medicament active ingredients are preferably nuclear export in-<br>
hibitors. Nuclear export inhibitors prevent the output of biopolymers (for<br>
example RNA) from the cell nucleus. Preferred nuclear export inhibitors<br>
are selected from the group callystatin, leptomycin B, ratjadone.<br>
Further medicament active ingredients are preferably immunosuppres-<br>
sants. Preferred immunosuppressants are selected from the group rapa-<br>
mycin, CCI-779 (Wyeth), RAD001 (Novartis), AP23573 (Ariad Pharmaceu-<br>
ticals).<br>
The invention also relates to a set (kit) consisting of separate packs of<br>
(a) an effective amount of a compound of the formula I and/or pharma-<br>
ceutically usable derivatives, solvates and stereoisomers thereof,<br>
including mixtures thereof in all ratios,<br>
and<br>
(b) an effective amount of a further medicament active ingredient.<br>
The set comprises suitable containers, such as boxes, individual bottles,<br>
bags or ampoules. The set may, for example, comprise separate am-<br>
poules, each containing an effective amount of a compound of the formula<br>
I and/or pharmaceutical usable derivatives, solvates and stereoisomers<br>
thereof, including mixtures thereof in all ratios,<br>
and an effective amount of a further medicament active ingredient in dis-<br>
solved or lyophilised form.<br><br>
-48-<br>
USE<br>
The present compounds are suitable as pharmaceutical active ingredients<br>
for mammals, in particular for humans, in the treatment of diseases in<br>
which HSP90 plays a role.<br>
The invention thus relates to the use of compounds of the formula I, and<br>
pharmaceutical usable derivatives, solvates and stereoisomers thereof,<br>
including mixtures thereof in all ratios, for the preparation of a medicament<br>
for the treatment of diseases in which the inhibition, regulation and/or<br>
modulation of HSP90 plays a role.<br>
Preference is given to the use of compounds of the formula I and pharma-<br>
ceutical usable derivatives, solvates and stereoisomers thereof, including<br>
mixtures thereof in all ratios, for the preparation of a medicament for the<br>
treatment of tumour diseases, for example fibrosarcoma, myxosarcoma,<br>
liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angio-<br>
sarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelio-<br>
sarcoma, synovioma, mesothelioma, Ewing's tumour, leiosarcoma, rhab-<br>
domyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovar-<br>
ian cancer, prostate cancer, squamous cell carcinoma, basal cell carci-<br>
noma, adenocarcinoma, syringocarcinoma, sebaceous gland carcinoma,<br>
papillary carcinoma, papillary adenocarcinomas, cystadenocarcinomas,<br>
bone marrow carcinoma, bronchogenic carcinoma, renal cell carcinoma,<br>
hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonic<br>
carcinoma, Wilm's tumour, cervical cancer, testicular tumour, lung carci-<br>
noma, small-cell lung carcinoma, bladder carcinoma, epithelial carcinoma,<br>
glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma,<br>
pinealoma, haemangioblastoma, acoustic neuroma, oligodendroglioma,<br>
meningioma, melanoma, neuroblastoma, retinoblastoma, leukaemia, lym-<br><br>
-49-<br>
phoma, multiple myeloma, Waldenstrom's macroglobulinaemia and heavy<br>
chain disease;<br>
viral diseases, where the viral pathogen is selected from the group con-<br>
sisting of hepatitis type A, hepatitis type B, hepatitis type C, influenza,<br>
varicella, adenovirus, herpes simplex type I (HSV-I), herpes simplex type II<br>
(HSV-II), cattle plague, rhinovirus, echovirus, rotavirus, respiratory syn-<br>
cytial virus (RSV), papillomavirus, papovavirus, cytomegalovirus, echino-<br>
virus, arbovirus, huntavirus, Coxsackie virus, mumps virus, measles virus,<br>
rubella virus, polio virus, human immunodeficiency virus type I (HIV-I) and<br>
human immunodeficiency virus type II (HIV-II);<br>
for immune suppression in transplants; inflammation-induced diseases,<br>
such as rheumatoid arthritis, asthma, multiple sclerosis, type 1 diabetes,<br>
lupus erythematosus, psoriasis and inflammatory bowel disease; cystic<br>
fibrosis; diseases associated with angiogenesis, such as, for example, dia-<br>
betic retinopathy, haemangioma, endometriosis, tumour angiogenesis;<br>
infectious diseases; autoimmune diseases; ischaemia; promotion of nerve<br>
regeneration; fibrogenetic diseases, such as, for example, sclerorma,<br>
polymyositis, systemic lupus, cirrhosis of the liver, keloid formation, inter-<br>
stitial nephritis and pulmonary fibrosis;<br>
The compounds of the formula I can inhibit, in particular, the growth of<br>
cancer, tumour cells and tumour metastases and are therefore suitable for<br>
tumour therapy.<br>
The present invention furthermore encompasses the use of the com-<br>
pounds of the formula I and/or physiologically acceptable salts and sol-<br>
vates thereof for the preparation of a medicament for the protection of<br>
normal cells against toxicity caused by chemotherapy, and for the treat-<br>
ment of diseases in which incorrect protein folding or aggregation is a prin-<br>
cipal causal factor, such as, for example, scrapie, Creutzfeldt-Jakob dis-<br>
ease, Huntington's or Alzheimer's.<br><br>
-50-<br>
The invention also relates to the use of the compounds of the formula I<br>
and/or physiologically acceptable salts and solvates thereof for the prepa-<br>
ration of a medicament for the treatment of diseases of the central nervous<br>
system, of cardiovascular diseases and cachexia.<br>
In a further embodiment, the invention also relates to the use of the com-<br>
pounds of the formula I and/or physiologically acceptable salts and sol-<br>
vates thereof for the preparation of a medicament for HSP90 modulation,<br>
where the modulated biological HSP90 activity causes an immune reaction<br>
in an individual, protein transport from the endoplasmatic reticulum, recov-<br>
ery from hypoxic/anoxic stress, recovery from malnutrition, recovery from<br>
heat stress, or combinations thereof, and/or where the disorder is a type of<br>
cancer, an infectious disease, a disorder associated with disrupted protein<br>
transport from the endoplasmatic reticulum, a disorder associated with<br>
ischaemia/reperfusion, or combinations thereof, where the the disorder<br>
associated with ischaemia/reperfusion is a consequence of cardiac arrest,<br>
asystolia and delayed ventricular arrhythmia, heart operation, cardio-<br>
pulmonary bypass operation, organ transplant, spinal cord trauma, head<br>
trauma, stroke, thromboembolic stroke, haemorrhagic stroke, cerebral<br>
vasospasm, hypotonia, hypoglycaemia, status epilepticus, an epileptic fit,<br>
anxiety, schizophrenia, a neurodegenerative disorder, Alzheimer's disease,<br>
Huntington's disease, amyotrophic lateral sclerosis (ALS) or neonatal<br>
stress.<br>
In a further embodiment, the invention also relates to the use of the com-<br>
pounds of the formula I and/or physiologically acceptable salts and sol-<br>
vates thereof for the preparation of a medicament for the treatment of<br>
ischaemia as a consequence of cardiac arrest, asystolia and delayed ven-<br>
tricular arrhythmia, heart operation, cardiopulmonary bypass operation,<br>
organ transplant, spinal cord trauma, head trauma, stroke, thromboembolic<br>
stroke, haemorrhagic stroke, cerebral vasospasm, hypotonia, hypoglycae-<br>
mia, status epilepticus, an epileptic fit, anxiety, schizophrenia, a neuro-<br><br>
-51 -<br>
degenerative disorder, Alzheimer's disease, Huntington's disease, amyo-<br>
trophic lateral sclerosis (ALS) or neonatal stress.<br>
Test method for the measurement of HSP90 inhibitors<br>
The binding of geldanamycin or 17- allylamino-17-demethoxygeldana-<br>
mycin (17AAG) to HSP90 and competitive inhibition thereof can be utilised<br>
in order to determine the inhibitory activity of the compounds according to<br>
the invention (Carreras et al. 2003, Chiosis et al. 2002).<br>
In the specific case, a radioligand filter binding test is used. The radio-<br>
ligand used here is tritium-labelled 17-allylaminogeldanamycin,<br>
[3H]17AAG. This filter binding test allows a targeted search for inhibitors<br>
which interfere with the ATP binding site.<br><br>
-52-<br>
Material<br>
Recombinant human HSP90a (E. coli expressed, 95% purity);<br>
[3HJ17AAG (17-allylaminogeldanamycin, [allylamino-2,3-3H. Specific activ-<br>
ity: 1.11x1012 Bq/mmol (Moravek, MT-1717);<br>
HEPES filter buffer (50 mM HEPES, pH 7.0, 5 mM MgCI2, BSA 0.01%)<br>
Multiscreen FB (1 urn) filter plate (Millipore, MAFBNOB 50).<br>
Method<br>
The 96-well microtitre filter plates are firstly irrigated and coated with 0.1%<br>
of polyethylenimine.<br>
The test is carried out under the following conditions:<br>
Reaction temperature 22C<br>
Reaction time: 30 min., shaking at 800 rpm<br>
Test volume: 50 ul<br>
Final concentrations:<br>
50 mM HEPES HCI, pH 7.0, 5 mM MgCI2, 0.01% (w/v) BSA<br>
HSP90: 1.5ug/assay<br>
[3H]17AAG:0.08uM.<br>
At the end of the reaction, the supernatant in the filter plate is removed by<br>
suction with the aid of a vacuum manifold (Multiscreen Separation System,<br>
Millipore), and the filter is washed twice.<br>
The filter plates are then measured in a beta counter (Microbeta, Wallac)<br>
with scintillator (Microscint 20, Packard).<br>
"% of control" is determined from the "counts per minutes" values and the<br>
IC-50 value of a compound is calculated therefrom.<br><br>
-53-<br>
Above and below, all temperatures are indicated inC. In the following<br>
examples, "conventional work-up" means: if necessary, water is added, the<br>
pH is adjusted, if necessary, to between 2 and 10, depending on the con-<br>
stitution of the end product, the mixture is extracted with ethyl acetate or<br>
dichloromethane, the phases are separated, the organic phase is dried<br>
over sodium sulfate and evaporated, and the product is purified by chro-<br>
matography on silica gel and/or by crystallisation. Rf values on silica gel;<br>
eluent: ethyl acetate/methanol 9:1.<br>
LC-MS conditions<br>
HP 1100 series Hewlett Packard System having the following features: ion<br>
source: electrospray (positive mode); scan: 100-1000 m/e; fragmentation<br>
voltage: 60 V; gas temperature: 300C, DAD: 220 nm.<br>
Flow rate: 2.4 ml/min. The splitter used reduced the flow rate for the MS to<br>
0.75 ml/min. after the DAD.<br>
Column: Chromolith SpeedROD RP-18e 50-4.6<br>
Solvent: LiChrosolv quality from Merck KGaA<br>
Solvent A: H20 (0.01 % of TFA)<br>
Solvent B: ACN (0.008% of TFA)<br>
Gradient:<br>
20% of B -&gt; 100% of B: 0 min to 2.8 min<br>
100% of B: 2.8 min to 3.3 min<br>
100% of B -&gt; 20% of B: 3.3 min to 4 min<br>
The retention times Rf [min] and M+H+ data MW indicated in the following<br>
examples are the measurement results of the LC-MS measurements.<br><br>
-54-<br>
Example 1<br>
Preparation of 2-amino-6-chloro-4-[3-(3-methoxycarbonylpropionylamino)-<br>
phenyl]quinazoline ("A1"):<br>
1.1	Reaction procedure analogous to Okabe, Masami; Sun, Ruen-Chu;<br>
Tetrahedron (1995), 51(7), 1861-6<br>
1 litre of glacial acetic acid and 10 litres of ice-water are added to a solu-<br>
tion of 2.0 kg of methyl 2-aminobenzoate in 15 litres of dichloromethane.<br>
1.9 kg of calcium hypochlorite are added at 10 with vigorous stirring, dur-<br>
ing which the temperature should not rise above 15. The mixture is stirred<br>
for a further 6 hours and left to stand for 16 hours. The dichloromethane is<br>
separated off, the aqueous phase is washed with dichloromethane, and<br>
the combined organic phases are washed with a 10% Na2S03 solution<br>
(warming!). The combined dichloromethane phases are stirred with 2 kg of<br>
silica gel, 200 g of activated carbon and 2 kg of sodium sulfate. The<br>
phases are separated, the dichloromethane is removed, 10 litres of n-<br>
hexane are added, the mixture is left to stand at 0-5 for 16 hours, and the<br>
product'isseparated off, giving 1.6 kg of methyl 2-amino-5-chlorobenzoate<br>
("1").<br>
1.2	A solution of 1 kg of sodium cyanate in 10 litres of water is added<br>
dropwise with stirring and cooling to a solution of 1.6 kg of "1" in 5 litres of<br>
glacial acetic acid. The mixture is stirred at room temperature for a further<br>
16 hours. 300 g of sodium cyanate are again added, and the mixture is<br>
stirred for a further 4 hours. The precipitate is separated off, suspended in<br>
15 I of water at 60, and 1 I of cone. NaOH is added. The mixture is stirred<br>
at 96 for 1 hour, left to stand at room temperature for 16 hours, and the<br>
precipitate is then separated off. The latter is suspended in 6 litres of hot<br>
ethanol and separated off. The product is dried at 100 for 16 hours, giving<br>
978 g of 6-chloro-2,4-dihydroxyquinazoline ("2").<br><br>
-55-<br>
1.3	A mixture of 391 ml of phosphoryl chloride and 0.888 kg of<br>
phosphorus pentachloride is warmed to 80. 391 g of "2" are then added in<br>
portions without further warming. The mixture is warmed to 135, the<br>
phosphoryl chloride is distilled off, and the mixture is stirred at 135 for a<br>
further 10 hours. At 45, the reaction mixture is poured onto 10 litres of ice<br>
and stirred for a further 3 hours. The mixture is extracted by shaking three<br>
times with 3 litres of dichloromethane, dried, giving, after crystallisation,<br>
310 g of 2,4,6-trichloroquinazoline ("3").<br>
1.4	The following are combined under an argon atmosphere: 100 mg of<br>
"3", 107 mg of 3-nitrophenylboronic acid, 25 mg of tetrakis(triphenyl-<br>
phosphine)palladium(O), 90 mg of potassium carbonate and 4 ml of tolu-<br>
ene. The mixture is stirred at 100 for 16 hours. The mixture is allowed to<br>
cool and filtered through kieselguhr with suction. The solvent is removed,<br>
and the residue is purified by chromatography, giving 116 mg of 2,6-di-<br>
chloro-4-(3-nitrophenyl)quinazoline ("4").<br>
1.5	A solution of 700 mg of "4" and 0.7 g of ammonia in 10 ml of THF is<br>
stirred at 80 under pressure for 21 hours. Removal of the solvent gives<br>
2-amino-6-chloro-4-(3-nitrophenyl)quinazoline ("5").<br>
1.6	800 mg of "5" are hydrogenated by standard methods in 30 ml of<br>
THF and using 800 mg of Raney nickel (water-wet). The catalyst is sepa-<br>
rated off, the solvent is removed and crystallised from 10 ml of ethanol.<br>
Drying gives 527 mg of 2-amino-6-chloro-4-(3-aminophenyl)quinazoline<br>
("6").<br>
1.7	50 ul of methyl succinate chloride are added to a solution of 100 mg<br>
of "6" and 36 pi of pyridine in 4 ml of dichloromethane, and the mixture is<br>
stirred at room temperature for a further 4 hours. 1 N HCI is added, and<br><br>
-56-<br>
the precipitated product is separated off. The product is washed with<br>
water, dried, giving 109 mg of "A1"<br><br>
Analogous reaction of "6" with<br>
3-(trifluoromethyl)benzoyl chloride,<br>
2-methylbenzoyl chloride,<br>
3-methylbenzoyl chloride,<br>
4-methylbenzoyl chloride,<br>
3-(trifluoromethyl)benzoyl chloride,<br>
2-fluorobenzoyl chloride,<br>
3-chlorobenzoyl chloride,<br>
4-chlorobenzoyl chloride,<br>
4-(trifluoromethyl)benzoyl chloride,<br>
acetyl chloride,<br>
trifluoroacetic anhydride,<br>
propionyl chloride,<br>
isobutyryl chloride,<br>
picolinyl chloride,<br>
isonicotinyl chloride,<br>
nicotinyl chloride,<br>
4-methoxycarbonylbenzoyl chloride,<br>
3-fluorobenzoyl chloride,<br>
4-fluorobenzoyl chloride,<br>
2-chlorobenzoyl chloride,<br><br>
-57-<br>
benzoyl chloride,<br>
gives the compounds<br>
2-amino-6-chloro-4-[3-(3-trifluoromethylbenzoylamino)phenyl]quina-<br>
zoline ("A2"),<br>
2-amino-6-chloro-4-[3-(2-methylbenzoylamino)phenyl]quinazoline<br>
("A4"),<br>
2-amino-6-chloro-4-[3-(3-methylbenzoylamino)phenyl]quinazoline<br>
("A5"),<br>
2-amino-6-chloro-4-[3-(4-methylbenzoylamino)phenyl]quinazoline<br>
("A6"),<br>
2-amino-6-chloro-4-[3-(2-trifluoromethylbenzoylamino)phenyl]quina-<br>
zoline ("A7"),<br>
2-amino-6-chloro-4-[3-(2-fluorobenzoylamino)phenyl]quinazoline<br>
("A8"),<br>
2-amino-6-chloro-4-[3-(3-chlorobenzoylamino)phenyl]quinazoline<br>
("A9"),<br>
2-amino-6-chloro-4-[3-(4-chlorobenzoylamino)phenyl]quinazoline<br>
("A10"),<br>
2-amino-6-chloro-4-[3-(4-trifluoromethylbenzoylamino)phenyl]quina-<br>
zoline ("A16"),<br>
2-amino-6-chloro-4-(3-acetamidophenyl)quinazoline ("A17"),<br>
2-amino-6-chloro-4-(3-trifluoroacetamidophenyl)quinazoline ("A18"),<br>
2-amino-6-chloro-4-(3-propionylaminophenyl)quinazoline ("A19"),<br>
2-amino-6-chloro-4-(3-isobutyrylaminophenyl)quinazoline ("A20"),<br>
2-amino-6-chloro-4-[3-(pyridin-2-ylcarbonylamino)phenyl]quinazoline<br>
("A21"),<br>
2-amino-6-chloro-4-[3-(pyridin-4-ylcarbonylamino)phenyl]quinazoline<br>
("A22"),<br>
2-amino-6-chloro-4-[3-(pyridin-3-ylcarbonylamino)phenyl]quinazoline<br>
("A23"),<br><br>
-58-<br>
2-amino-6-chloro-4-[3-(4-methoxycarbonylbenzoylamino)phenyl]-<br>
quinazoline ("A28"),<br>
2-amino-6-chloro-4-[3-(3-fluorobenzoylamino)phenyl]quinazoline<br>
("A29"),<br>
2-amino-6-chloro-4-[3-(4-fluorobenzoylamino)phenyl]quinazoline<br>
("A30"),<br>
2-amino-6-chloro-4-[3-(2-chlorobenzoylamino)phenyl]quinazoline<br>
("A31"),<br>
2-amino-6-chloro-4-(3-benzoylaminophenyl)quinazoline ("A32").<br>
Example 2<br>
48 mg of "A1" in 2 ml of ammonia/THF solution (0.5 M solution in 1,4-di-<br>
oxane) are irradiated in the microwave. Removal of the solvent gives<br>
2-amino-6-chloro-4-[3-(3-aminocarbonylpropionylamino)phenyl]quinazoline<br>
("A3").<br>
Example 3<br>
106.2 mg of /V-(3-dimethylaminopropyl)-/V-ethylcarbodiimide hydrochloride<br>
(DAPECI) and 56 mg of A/-methylmorpholine are added to a solution of<br>
73.6 mg of 1 H-indole-7-carboxylic acid and 67.9 mg of 1-hydroxybenzo-<br>
triazole hydrate (HOBt) in 1 ml of DMF. The mixture is stirred at room tem-<br>
perature for 1 hour. 100 mg of "6" are then added, and the mixture is<br>
stirred for 16 hours. The mixture is stirred into 10 ml of water, the precipi-<br>
tated material is separated off and washed with water. The residue is<br>
boiled once with 10 ml of acetonitrile/water and dried, giving 132 mg of<br>
2-amino-6-chloro-4-[3-(indol-7-ylcarbonylamino)phenyl]quinazoline ("A11").<br>
Analogous reaction of "6" with<br><br>
-59-<br>
BOC-p-Ala-OH (BOC-p-alanine),<br>
BOC-GABA-OH (BOC-y-aminobutyric acid),<br>
BOC-Ala-OH (BOC-(S)-alanine),<br>
BOC-(R)-Ala-OH(BOC-(R)-alanine),<br>
BOC-Ser(0-tert-butyl)-OH (BOC-(S)-serine tert-butyl ether),<br>
BOC-(R)-Ser(0-tert-butyl)-OH (BOC-(R)-serine tert-butyl ether),<br>
BOC-Thr(0-tert-butyl)-OH,<br>
BOC-(R)-Thr(0-tert-butyl)-OH,<br>
BOC-Asn-OH (BOC-asparagine),<br>
BOC-(R)-Asn-OH (BOC-(R)-asparagine),<br>
BOC-His-OH (BOC-histidine),<br>
1/-/-indazole-7-carboxylic acid,<br>
2-hydroxyisonicotinic acid<br>
gives the compounds<br>
2-amino-6-chloro-4-(3-{3-[(tert-butyloxycarbonyl)amino]propionyl-<br>
amino}phenyl)quinazoline ("A12"),<br>
2-amino-6-chloro-4-(3-{4-[(tert-butyloxycarbonyl)amino]butyrylamino}-<br>
phenyl)quinazoline ("A14"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]propionyl-<br>
amino}phenyl)quinazoline ("A24"),<br>
(R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]propionyl-<br>
amino}phenyl)quinazoline ("A26"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-(tert-<br>
butoxy)propionylamino}phenyl)quinazoline ("A32"),<br>
(R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-(tert-<br>
butoxy)propionylamino}phenyl)quinazoline ("A32a"),<br>
(2S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-(tert-<br>
butoxy)butyrylamino}phenyl)quinazoline ("A34"),<br><br>
-60-<br>
(2R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-(tert-<br>
butoxy)butyrylamino}phenyl)quinazoline ("A34a"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-amino-<br>
carbonylpropionylamino}phenyl)quinazoline ("A36"),<br>
(R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-amino-<br>
carbonylpropionylamino}phenyl)quinazoline ("A38"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-(1H-<br>
imidazol-4-yl)propionylamino}phenyl)quinazoline ("A40"),<br>
2-amino-6-chloro-4-[3-(indazol-7-ylcarbonylamino)phenyl]quinazoline<br>
("A42"),<br>
2-amino-6-chloro-4-[3-(2-hydroxypyridin-4-ylcarbonylamino)phenyl]-<br>
quinazoline ("A43").<br>
Analogous reaction of 2-amino-6-chloro-4-(2-aminophenyl)quinazoline with<br>
1H-indazole-7-carboxylic acid,<br>
2-hydroxyisonicotinic acid<br>
gives the compounds<br>
2-amino-6-chloro-4-[2-(indazol-7-ylcarbonylamino)phenyl]quinazoline<br>
("A42a"),<br>
2-amino-6-chloro-4-[2-(2-hydroxypyridin-4-ylcarbonylamino)phenyl]-<br>
quinazoline ("A43a").<br>
Example 4<br>
Removal of the BOC group and/or tert-butyl group in HCI/dioxane by stan-<br>
dard methods<br>
from "A12" gives the compound<br>
2-amino-6-chloro-4-[3-(3-aminopropionylamino)phenyl]quinazoline<br>
("A13");<br><br>
-61-<br>
from "A14" gives the compound<br>
2-amino-6-chloro-4-[3-(4-aminobutyrylamino)pheny1]quinazoline<br>
("A15");<br>
from "A24" gives the compound<br>
(S)-2-amino-6-chloro-4-[3-(2-aminopropionylamino)phenyl]quina-<br>
zoline ("A25");<br>
from "A26" gives the compound<br>
(R)-2-amino-6-chloro-4-[3-(2-aminopropionylamino)phenyl]quina-<br>
zoline ("A27");<br>
from "A32" gives the compound<br>
(S)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxypropionylamino)-<br>
phenyl]quinazoline ("A33")<br><br>
from "A32a" gives the compound<br>
(R)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxypropionylamino)-<br>
phenyl]quinazoiine ("A33a");<br>
from "A34" gives the compound<br>
(2S)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxybutyrylamino)phenyl]-<br>
quinazoline ("A35");<br>
from "A34a" gives the compound<br><br>
-62-<br>
(2R)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxybutyiylamino)phenyl]-<br>
quinazoline ("A35a");<br><br>
from "A36" gives the compound<br>
(S)-2-amino-6-chloro-4-[3-(2-amino-3-aminocarbonylpropionylamino)-<br>
phenyl]quinazoline ("A37")<br><br>
from "A38" gives the compound<br>
(R)-2-amino-6-chloro-4-[3-(2-amino-3-aminocarbonylpropionylamino)-<br>
phenyl]quinazoline ("A39");<br>
from "A49" gives the compound<br>
(R)-2-amino-6-chloro-4-[3-(2-amino-3-(1/-/-imidazol-4-yl)propionyl-<br>
amino)phenyl]quinazoline ("A41").<br><br>
-63-<br>
Example 5<br>
Reaction of "3" with 5-fluoro-4-methoxy-2-nitrophenylboronic acid analo-<br>
gously to Example 1.4 gives the compound<br>
2,6-dichloro-4-(5-fluoro-4-methoxy-2-nitrophenyl)quinazoline;<br>
and analogously to Example 1.5 and 1.6 this gives the compound<br>
2-amino-6-chloro-4-(5-fluoro-4-methoxy-2-aminophenyl)quinazoline.<br>
Reaction thereof with benzoyl chloride analogously to Example 1.7 gives<br>
the compound<br>
2-amino-6-chloro-4-[5-fluoro-4-methoxy-2-benzoylaminophenyl]-<br>
quinazoline ("A44").<br>
Example 6<br>
Reaction of 2-amino-6-chloro-4-(3-amino-4-chlorophenyl)quinazoline with<br>
BOC-2-(1/-/-imidazol-4-yl)glycine analogously to Example 3 gives the com-<br>
pound<br>
and removal of the BOC group therefrom gives the compound<br>
2-amino-6-chloro-4-(4-chloro-3-{2-[(tert-butyloxycarbonyl)amino]-2-<br>
(1 /-/-imidazol-4-yl)acetamido}phenyl)quinazoline ("A45"),<br><br><br>
-64-<br>
2-amino-6-chloro-4-{4-chloro-3-[2-amino-2-(1H-imidazol-4-yl)-<br>
acetamido]phenyl}quinazoline ("A46").<br>
The compound<br>
2-amino-6-chloro-4-{4-chloro-2-[2-amino-2-(1H-imidazol-4-yl)-<br>
acetamido]phenyl}quinazoline ("A47")<br>
is obtained analogously.<br>
Example 7<br>
Reaction of 2-amino-7-methyl-4-(3-amino-5-chlorophenyl)quinazoline with<br>
4-isocyanatobenzoic acid under standard conditions and conventional<br>
work-up gives the compound<br>
4-{3-[3-(2-amino-7-methylquinazolin-4-yl)-5-chlorophenyl]ureido}ben-<br>
zoic acid ("A48")<br><br>
The compound 4-{3-[2-(2-amino-7-methylquinazolin-4-yl)-5-chlorophenyl]-<br>
ureido}benzoic acid ("A49") is obtained analogously.<br>
Example 8<br>
Reaction of 2-amino-6-methoxy-4-(3-amino-4-methoxyphenyl)quinazoline<br>
with 3-fluorophenylsulfonyl chloride analogously to Example 1 gives the<br>
compound<br><br>
-65-<br>
2-amino-6-methoxy-4-[4-methoxy-3-(3-fluorophenylsulfonamido)-<br>
phenyl]quinazoline ("A50");<br>
and reaction of 2-amino-6-methoxy-4-(2-amino-4-methoxyphenyl)quina-<br>
zoline with 3-fluorophenylsulfonyl chloride gives the compound<br>
2-amino-6-methoxy-4-[4-methoxy-2-(3-fluorophenylsulfonamido)-<br>
phenyl]quinazoline ("A51").<br>
Example 9<br>
9.1	The following are combined under an argon atmosphere: 100 mg of<br>
"3", 160 mg of 3-(tert-butyldimethylsilyloxy)phenylboronic acid, 25 mg of<br>
tetrakis(triphenylphosphine)palladium(0), 90 mg of potassium carbonate<br>
and 4 ml of toluene. The mixture is stirred at 100 for 16 hours. The mix-<br>
ture is allowed to cool and filtered through kieselguhr with suction. The sol-<br>
vent is removed, and the residue is purified by chromatography, giving<br>
105 mg of 2,6-dichloro-4-(3-tert-butyldimethylsilyloxyphenyl)quinazoline.<br>
9.2	Reaction of 2,6-dichloro-4-(3-tert-butyldimethylsilyloxyphenyl)quina-<br>
zoline with ammonia under pressure analogously to Example 1.5 gives the<br>
compound<br>
2-amino-6-chloro-4-(3-hydroxyphenyl)quinazoline.<br>
9.3	Reaction of 2-amino-6-chloro-4-(3-hydroxyphenyl)quinazoline with<br>
3-trifluoromethylbenzyl chloride under standard conditions and conven-<br>
tional work-up gives the compound<br>
2-amino-6-chloro-4-[3-(3-trifluoromethylbenzyloxy)phenyl]quinazoline<br>
("A56").<br>
Analogous reaction of 2-amino-6-chloro-4-(2-hydroxyphenyl)quinazoline<br>
with 3-trifluoromethylbenzyl chloride gives the compound<br><br>
-66-<br>
2-amino-6-chloro-4-[2-(3-trifluoromethylbenzyloxy)phenyl]quinazoline<br>
("A57").<br>
Example 10<br>
The preparation of 2-amino-6-aminocarbonylmethoxy-4-(4-methoxy-3-<br>
acetamidophenyl)quinazoline ("A52") is carried out as indicated in the fol-<br>
lowing scheme:<br><br><br>
-67-<br>
The compound 2-amino-6-aminocarbonylmethoxy-4-(4-methoxy-2-<br>
acetamidophenyl)quinazoline ("A53") is obtained analogously<br>
Example 11<br>
The preparation of 2-amino-4-[4-ethoxy-3-(2-hydroxyethoxy)phenyl]-6-[2-<br>
(4-methylpiperazin-1-yl)ethoxy]quinazoline ("A54") is carried out as indi-<br>
cated in the following scheme:<br><br><br>
-68-<br>
The compound 2-amino-4-[4-ethoxy-2-(2-hydroxyethoxy)phenyl]-6-[2-(4-<br>
methylpiperazin-1-yl)ethoxy]quinazoline ("A55") is obtained analogously.<br>
Example 12<br>
Reaction of 2-amino-6-chloro-4-(3-hydroxy-4-methoxyphenyl)quinazoline<br>
with methyl 4-chlorobutyrate under standard conditions and conventional<br>
work-up gives the compound<br>
2-amino-6-chloro-4-[3-(3-methoxycarbonylpropoxy)-4-methoxy-<br>
phenyl]quinazoline.<br>
Hydrolysis of the methyl ester thereof gives<br>
2-amino-6-chloro-4-[3-(3-carboxypropoxy)-4-methoxyphenyl]quina-<br>
zoline ("A58").<br>
Analogous reaction of 2-amino-6-chloro-4-(2-hydroxy-4-methoxyphenyl)-<br>
quinazoline with methyl 4-chlorobutyrate and ester hydrolysis gives the<br>
compound<br>
2-amino-6-chloro-4-[2-(3-carboxypropoxy)-4-methoxyphenyl]quina-<br>
zoline ("A59").<br>
Analogous reaction of 2-amino-6-chloro-4-(3-hydroxy-5-methoxyphenyl)-<br>
quinazoline with methyl 4-chlorobutyrate and ester hydrolysis gives the<br>
compound<br>
2-amino-6-chloro-4-[3-(3-carboxypropoxy)-5-methoxyphenyl]quina-<br>
zoline ("A66").<br>
Analogous reaction of 2-amino-6-chloro-4-(2-hydroxy-5-methoxyphenyl)-<br>
quinazoline with methyl 4-chlorobutyrate and ester hydrolysis gives the<br>
compound<br><br>
-69-<br>
2-amino-6-chloro-4-[2-(3-carboxypropoxy)-5-methoxyphenyl]quina-<br>
zoline ("A67").<br>
Example 13<br>
Reaction of 2-amino-6-aminomethylcarbonylamino-4-(3-hydroxyphenyl)-<br>
quinazoline with 4-chlorobutyramide under standard conditions and con-<br>
ventional work-up gives the compound<br>
2-amino-6-aminomethylcarbonylamino-4-[3-(3-aminocarbonyl-<br>
propoxy)phenyl]quinazoline ("A60").<br>
Analogous reaction of 2-amino-6-aminomethylcarbonylamino-4-(2-<br>
hydroxyphenyl)quinazoline with 4-chlorobutyramide gives the compound<br>
2-amino-6-aminomethylcarbonylamino-4-[2-(3-aminocarbonylpropoxy)-<br>
phenyl]quinazoline ("A61").<br>
Example 14<br>
14.1	Reaction of 2-amino-6-chloro-4-(3-hydroxyphenyl)quinazoline with<br>
tert-butyloxycarbonyl-NH-CH2CH2-Br under standard conditions and con-<br>
ventional work-up gives the compound<br>
2-amino-6-chloro-4-{3-[2-(tert-butyloxycarbonylamino)ethoxy]phenyl}-<br>
quinazoline.<br>
14.2	Removal of the BOC group in TFA/dichloromethane gives the<br>
compound<br>
2-amino-6-chloro-4-[3-(2-aminoethoxy)phenyl]quinazoline.<br>
14.3	Reaction thereof with 2-fluorophenyl isocyanate under standard<br>
conditions and conventional work-up gives the compound<br>
2-amino-6-chloro-4-(3-{2-[3-(2-fluorophenyl)ureido]ethoxy}phenyl)-<br>
quinoline ("A62")<br><br>
-70-<br><br>
Example 15<br>
15.1	Reaction of 2-amino-7-methoxy-4-(3-hydroxyphenyl)quinazoline<br>
with Br-CH2CH2-OH under standard conditions and conventional work-up<br>
gives the compound<br>
2-amino-7-methoxy-4-[3-(2-hydroxyethoxy)phenyl]quinazoline.<br>
15.2	Reaction thereof with 3-chloropropionamide and conventional<br>
work-up gives the compound<br>
2-amino-7-methoxy-4-{3-[2-(2-carbamoylethoxy)ethoxy]phenyl]quina-<br>
zoline ("A63")<br><br>
Example 16<br>
Reaction of 2-amino-4-(3-amino-2,4-dichlorophenyl)quinazoline with<br>
methoxycarbonylmethoxyacetic acid analogously to Example 3 and co<br>
ventional work-up gives the compound<br><br>
-71 -<br><br>
and ester cleavage thereof gives the compound<br>
{[3-(2-aminoquinazolin-4-yl)-2,4-dichlorophenylcarbamoyl]methoxy}-<br>
acetic acid ("A64").<br>
Analogous reaction of 2-ammo-4-(2-amino-4-chlorophenyl)quinazoline with<br>
methoxycarbonylmethoxyacetic acid, ester cleavage and conventional<br>
work-up gives the compound<br>
{[2-(2-aminoquinazolin-4-yl)-4-chlorophenylcarbamoyl]methoxy}acetic<br>
acid ("A65").<br>
Example 17<br>
Reaction of 2-amino-6-chloro-4-(3-carboxymethoxyphenyl)quinazoline with<br>
phenylalanine methyl ester analogously to Example 3, ester cleavage and<br>
conventional work-up gives the compound<br>
2-{2-[3-(2-amino-6-chloroquinazolin-4-yl)phenoxy]acetylamino-3-<br>
phenylpropionic acid ("A68")<br><br><br>
-72-<br>
Example 18<br>
Reaction of 2-amino-6-chloro-4-(2-carboxymethoxy-3,4-dichlorophenyl)-<br>
quinazoline with phenylalanine amide analogously to Example 3 and con-<br>
ventional work-up gives the compound<br>
2-{2-[2-(2-amino-6-chloroquinazolin-4-yl)-5,6-dichlorophenoxy]acetyl-<br>
amino-3-phenylpropionic acid ("A69")<br><br>
Example 19<br>
The compound<br>
The preparation of 2-amino-6-fluoro-4-[3-(4-methylpiperazin-1-yl)phenyl]-<br>
quinazoline ("A70") is carried out as indicated in the following scheme:<br><br><br>
-73-<br>
2-amino-6-fluoro-4-[2-(4-methylpiperazin-1-yl)-6-fluorophenyl]quina-<br>
zoline("A71")<br>
is obtained analogously.<br>
Example 20<br>
The preparation of 2-amino-6-fluoro-4-[3-(1H-indol-7-ylaminocarbonyl)-4-<br>
methoxyphenyljquinazoline ("A72") is carried out as indicated in the fol-<br>
lowing scheme:<br><br>
The compound<br>
2-amino-6-fluoro-4-[2-(1H-indol-7-ylaminocarbonyl)-4-methoxy-<br>
phenyl]quinazoline ("A73")<br>
is obtained analogously.<br><br>
-74-<br>
The following examples relate to pharmaceutical compositions:<br>
Example A: Injection vials<br>
A solution of 100 g of an active ingredient according to the invention and<br>
5 g of disodium hydrogenphosphate in 3 I of bidistilled water is adjusted to<br>
pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection<br>
vials, lyophilised under sterile conditions and sealed under sterile condi-<br>
tions. Each injection vial contains 5 mg of active ingredient.<br>
Example B: Suppositories<br>
A mixture of 20 g of an active ingredient according to the invention with<br>
100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into<br>
moulds and allowed to cool. Each suppository contains 20 mg of active<br>
ingredient.<br>
Example C: Solution<br>
A solution is prepared from 1 g of an active ingredient according to the<br>
invention, 9.38 g of NaH2P04  2 H20, 28.48 g of Na2HP04  12 H20 and<br>
0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is<br>
adjusted to 6.8, and the solution is made up to 1 I and sterilised by irradia-<br>
tion. This solution can be used in the form of eye drops.<br>
Example D: Ointment<br>
500 mg of an active ingredient according to the invention are mixed with<br>
99.5 g of Vaseline under aseptic conditions.<br><br>
-75-<br>
Example E: Tablets<br>
A mixture of 1 kg of active ingredient according to the invention, 4 kg of<br>
lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium<br>
stearate is pressed in a conventional manner to give tablets in such a way<br>
that each tablet contains 10 mg of active ingredient.<br>
Example F: Dragees<br>
Tablets are pressed analogously to Example E and subsequently coated<br>
in a conventional manner with a coating of sucrose, potato starch, talc,<br>
tragacanth and dye.<br>
Example G: Capsules<br>
2 kg of active ingredient according to the invention are introduced into<br>
hard gelatine capsules in a conventional manner in such a way that each<br>
capsule contains 20 mg of the active ingredient.<br>
Example H: Ampoules<br>
A solution of 1 kg of an active ingredient according to the invention in 60 I<br>
of bidistilled water is sterile filtered, transferred into ampoules, lyophilised<br>
under sterile conditions and sealed under sterile conditions. Each ampoule<br>
contains 10 mg of active ingredient.<br><br>
-76-<br>
Patent Claims<br>
1. Compounds of the formula I<br><br>
in which<br>
R1	denotes Hal, OH, OA, SH, SA, H or A,<br>
R2, R3	each, independently of one another, denote -0-(X)s-Q,<br>
-S-(X)S-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-CONA-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)0-(X)s-Q,<br>
-NHS02-(X)s-Q, -S02NH-(X)s-Q, -S02NA-(X)s-Q,<br>
NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 * H, or<br>
if R3 = H, then R2 * H,<br>
R4, R5	each, independently of one another, denote H, Hal, CN,<br>
N02, A, OH, OA, SH, SA, (CH2)nCOOH, (CH2)nCOOA,<br>
0(CH2)0CONH2, CONHA, CONAA', NH2, NHA, NAA',<br>
NHCOOA, NHCO(CH2)nNH2, NHCONHA, SOA, S02A,<br>
S02NH2, S02NHA, S02NAA' or 0(CH2)0Het1,<br>
two adjacent radicals selected from the group R1, R2, R3<br>
together also denote methylenedioxy or ethylenedioxy,<br>
A, A'	each, independently of one another, denote unbranched<br>
or branched alkyl having 1-10 C atoms, in which 1-5 H<br>
atoms may be replaced by F, CI and/or Br,<br>
Alk or cyclic alkyl having 3-7 C atoms,<br><br>
-77-<br>
A and A' together also denote an alkylene chain having 2, 3, 4, 5<br>
or 6 C atoms, in which one or two CH2 groups may be<br>
replaced by 0, S, SO, S02, NH, NA and/or N-COOA,<br>
Alk	denotes alkenyl having 2-6 C atoms,<br>
X	denotes unbranched or branched C1-C10 alkylene or C2-<br>
C10 alkenylene, each of which is unsubstituted or mono-<br>
, di-, tri- or tetrasubstituted by A, OA, OH, SH, SA, Hal,<br>
N02, CN, Ar, OAr, COOH, COOA, CHO, C(=0)A,<br>
C(=0)Ar, S02A, CONH2, SO2NH2, CONHA, CONAA',<br>
SO2NHA, S02NAA\ NH2, NHA, NAA', OCONH2,<br>
OCONHA, OCONAA', NHCOA, NHCOOA, NACOOA,<br>
NHSO2OA, NAS02OA, NHCONH2, NACONH2,<br>
NHCONHA, NACONHA, NHCONAA', NACONAA'<br>
and/or =0 and in which one, two or three C groups may<br>
be replaced by O, S, SO, S02, NHCO, NACO, CONH,<br>
CONA, S02NH, S02NA, NHSO2, NAS02 and/or by NH<br>
groups,<br>
Q	denotes H, Carb, Ar or Het,<br>
Carb	denotes cycloalkyl having 3-7 C atoms or cycloalkenyl<br>
having 3-7 C atoms, each of which is unsubstituted or<br>
mono-, di-, tri-, tetra- or pentasubstituted by A, OA, OH,<br>
SH, SA, Hal, N02, CN, (CH2)nAr\ (CH2)nCOOH,<br>
(CH2)nCOOA, CHO, COA, S02A, CONH2, S02NH2,<br>
CONHA, CONAA', S02NHA, S02NAA\ NH2, NHA,<br>
NAA', OCONH2, OCONHA, OCONAA', NHCOA,<br>
NHCOOA, NACOOA, NHS02OA, NAS02OA,<br>
NHCONH2, NACONH2, NHCONHA, NACONHA,<br>
NHCONAA' or NACONAA',<br>
Ar	denotes phenyl, naphthyl or biphenyl, each of which is<br>
unsubstituted or mono-, di-, tri-, tetra- or pentasubsti-<br>
tuted by A, OA, OH, SH, SA, Hal, N02, CN, (CH2)nAr(CH2)nCOOH, (CH2)nCOOA, CHO, COA, S02A, CONH2,<br><br>
-78-<br>
S02NH2, CONHA, CONAA', S02NHA, S02NAA\ NH2,<br>
NHA, NAA', OCONH2, OCONHA, OCONAA*, NHCOA,<br>
NHCOOA, NACOOA, NHS02OA, NAS02OA,<br>
NHCONH2, NACONH2, NHCONHA, NACONHA,<br>
NHCONAA or NACONAA',<br>
Ar'	denotes phenyl, naphthyl or biphenyl, each of which is<br>
unsubstituted or mono-, di- or trisubstituted by A, OA,<br>
OH, SH, SA, Hal, N02, CN, (CH2)nphenyl, (CH2)nCOOH,<br>
(CH2)nCOOA, CHO, COA, S02A, CONH2, S02NH2,<br>
CONHA, CONAA', S02NHA, S02NAA', NH2) NHA,<br>
NAA', OCONH2, OCONHA, OCONAA', NHCOA,<br>
NHCOOA, NACOOA, NHS02OA, NAS02OA,<br>
NHCONH2, NACONH2, NHCONHA, NACONHA,<br>
NHCONAA' or NACONAA',<br>
Het	denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms,<br>
which may be mono-, di- or trisubstituted by A, OA, OH,<br>
SH, SA, Hal, N02, CN, (CH2)nAr\ (CH2)nCOOH,<br>
(CH2)nCOOA, CHO, COA, S02A, CONH2, S02NH2,<br>
CONHA, CONAA', S02NHA, S02NAA', NH2, NHA,<br>
NAA', OCONH2, OCONHA, OCONAA', NHCOA,<br>
NHCOOA, NACOOA, NHS02OA, NAS02OA,<br>
NHCONH2, NACONH2, .NHCONHA, NACONHA,<br>
NHCONAA", NACONAA', S02A, =S, =NH, =NA and/or<br>
=0 (carbonyl oxygen),<br>
Het1	denotes a monocyclic saturated, unsaturated or aro-<br>
matic heterocycle having 1 to 2 N and/or O atoms,<br>
which may be mono- or disubstituted by A, OA, OH, Hal<br>
and/or =0 (carbonyl oxygen),<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1, 2, 3 or 4,<br>
o	denotes 1, 2 or 3,<br><br>
-79-<br>
s	denotes 0 or 1,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
2.	Compounds according to Claim 1 in which<br>
R1 denotes Hal, OH, OA or H,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
3.	Compounds according to Claim 1 or 2 in which<br>
R2, R3 each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3  H, or<br>
if R3 = H, then R2 * H,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
4.	Compounds according to one or more of Claims 1-3 in which<br>
R4, R5 each, independently of one another, denote H, Hal, A, OH,<br>
OA, O(CH2)0CONH2, NHCO(CH2)nNH2 or 0(CH2)0Het1,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
5.	Compounds according to one or more of Claims 1-4 in which<br>
R4 denotes H, Hal, OHorOA,<br>
R5	denotes H, Hal, A, OH, OA, 0(CH2)0CONH2,<br>
NHCO(CH2)nNH2 or 0(CH2)0Het1,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br><br>
-80-<br>
6.	Compounds according to one or more of Claims 1-5 in which<br>
X	denotes unbranched or branched Ci-C10 alkylene which is<br>
unsubstituted or mono- or disubstituted by OA, OH, COOH,<br>
COOA, CONH2, NH2, NHA and/or NAA' and in which one,<br>
two or three C groups may be replaced by O, NHCO, CONH<br>
and/or by NH groups,<br>
and pharmaceutical usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
7.	Compounds according to one or more of Claims 1-6 in which<br>
Q	denotes H, Ar or Het,<br>
and pharmaceutical usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
8.	Compounds according to one or more of Claims 1-7 in which<br>
Ar	denotes phenyl which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, Hal, OA and/or (CH2)nCOOH<br>
and/or (CH2)nCOOA,<br>
and pharmaceutical usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
9.	Compounds according to one or more of Claims 1-8 in which<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aro-<br>
matic heterocycle having 1 to 4 N, O and/or S atoms, which<br>
may be mono-, di- or trisubstituted by A, OH, OA and/or Hal,<br>
and pharmaceutical usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
10.	Compounds according to one or more of Claims 1-9 in which<br>
Het denotes a mono- or bicyclic aromatic heterocycle having 1 to<br>
4 N, O and/or S atoms, which may be mono-, di- or trisubsti-<br>
tuted by A, OH, OA and/or Hal,<br><br>
-81 -<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
11.	Compounds according to one or more of Claims 1-10 in which<br>
Het1 denotes a monocyclic saturated heterocycle having 1 to 2 N<br>
and/or O atoms, which may be mono- or disubstituted by A<br>
and/or =0 (carbonyl oxygen),<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
12.	Compounds according to one or more of Claims 1-11 in which<br>
A	denotes unbranched or branched alkyl having 1-6 C<br>
atoms, in which 1-5 H atoms may be replaced by F<br>
and/or CI,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
13.	Compounds according to one or more of Claims 1-12 in which<br>
R1	denotes Hal, OH, OA or H,<br>
R2, R3 each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 * H, or<br>
if R3 = H, then R2 * H,<br>
R4, R5 each, independently of one another, denote H, Hal, A, OH,<br>
OA, 0(CH2)0CONH2, NHCO(CH2)nNH2 or 0(CH2)0Het1,<br>
X	denotes unbranched or branched CrCio alkylene which is<br>
unsubstituted or mono- or disubstituted by OA, OH, COOH,<br>
COOA, CONH2, NH2, NHA and/or NAA' and in which one,<br>
two or three C groups may be replaced by O, NHCO, CONH<br>
and/or by NH groups,<br><br>
-82-<br>
Q	denotes H, Ar or Het,<br>
Ar	denotes phenyl which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, Hal, OA and/or (CH2)nCOOH<br>
and/or (CH2)nCOOA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aro-<br>
matic heterocycle having 1 to 4 N, O and/or S atoms, which<br>
may be mono-, di- or trisubstituted by A, OH, OA and/or Hal,<br>
Het1 denotes a monocyclic saturated heterocycle having 1 to 2 N<br>
and/or O atoms, which may be mono- or disubstituted by A<br>
and/or =0 (carbonyl oxygen),<br>
A, A' each, independently of one another, denote unbranched or<br>
branched alkyl having 1-6 C atoms, in which 1-5 H atoms<br>
may be replaced by F and/or CI,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1, 2, 3 or 4,<br>
o	denotes 1, 2 or 3,<br>
s	denotes 0 or 1,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
14. Compounds according to one or more of Claims 1-13 in which<br>
R1	denotes Hal, OH, OA or H,<br>
R2, R3 each, independently of one another, denote -0-(X)s-Q,<br>
-NHCO-(X)s-Q, -CONH-(X)s-Q,<br>
-NH(CO)NH-(X)s-Q, -NHS02-(X)s-Q,<br>
-S02NH-(X)s-Q, NHCOA, Hal, Het or H,<br>
where, if R2 = H, then R3 * H, or<br>
if R3 = H, then R2  H,<br>
R4	denotes H, Hal, OH or OA,<br>
R5 denotes H, Hal, A, OH, OA, 0(CH2)0CONH2,<br>
NHCO(CH2)nNH2 or 0(CH2)0Het1,<br><br>
-83-<br>
X	denotes unbranched or branched CrCio alkylene which is<br>
unsubstituted or mono- or disubstituted by OA, OH, COOH,<br>
COOA, CONH2 and/or NH2 and in which one, two or three C<br>
groups may be replaced by 0, NHCO, CONH and/or by NH<br>
groups,<br>
Q	denotes H, Ar or Het,<br>
Ar	denotes phenyl which is unsubstituted or mono-, di-, tri-,<br>
tetra- or pentasubstituted by A, Hal, OA and/or (CH2)nCOOH<br>
and/or (CH2)nCOOA,<br>
Het denotes a mono- or bicyclic aromatic heterocycle having 1 to<br>
4 N, O and/or S atoms, which may be mono-, di- or trisubsti-<br>
tuted by A, OH, OA and/or Hal,<br>
Het1 denotes a monocyclic saturated heterocycle having 1 to 2 N<br>
and/or O atoms, which may be mono- or disubstituted by A<br>
and/or =0 (carbonyl oxygen),<br>
A	denotes unbranched or branched alkyl having 1-6 C atoms, in<br>
which 1-5 H atoms may be replaced by F and/or CI,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1, 2, 3 or 4,<br>
0	denotes 1, 2 or 3,<br>
s	denotes 0 or 1,<br>
and pharmaceutical usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
15. Compounds according to Claim 1 selected from the group<br>
2-amino-6-chloro-4-[3-(3-methoxycarbonylpropionylamino)-<br>
phenyl]quinazoline ("A1"),<br>
2-amino-6-chloro-4-[3-(3-trifluoromethylbenzoylamino)phenyl]-<br>
quinazoline ("A2"),<br>
2-amino-6-chloro-4-[3-(2-methylbenzoylamino)phenyl]quinazo-<br>
line ("A4"),<br><br>
-84-<br>
2-amino-6-chloro-4-[3-(3-methylbenzoylamino)phenyl]quinazo-<br>
line ("A5"),<br>
2-amino-6-chloro-4-[3-(4-methylbenzoylamino)phenyl]quinazo-<br>
line ("A6"),<br>
2-amino-6-chloro-4-[3-(2-trifluoromethylbenzoylamino)phenyl]-<br>
quinazoline ("A7"),<br>
2-amino-6-chloro-4-[3-(2-fluorobenzoylamino)phenyl]quinazoline<br>
("A8"),<br>
2-amino-6-chloro-4-[3-(3-chlorobenzoylamino)phenyl]quinazo-<br>
line ("A9"),<br>
2-amino-6-chloro-4-[3-(4-chlorobenzoylamino)phenyl]quinazo-<br>
line("A10"),<br>
2-amino-6-chloro-4-[3-(4-trifluoromethylbenzoylamino)phenyl]-<br>
quinazoline("A16"),<br>
2-amino-6-chloro-4-(3-acetamidophenyl)quinazoline ("A17"),<br>
2-amino-6-chloro-4-(3-trifluoroacetamidophenyl)quinazoline<br>
("A18"),<br>
2-amino-6-chloro-4-(3-propionylaminophenyl)quinazoline<br>
("A19"),<br>
2-amino-6-chloro-4-(3-isobutyrylaminophenyl)quinazoline<br>
("A20"),<br>
2-amino-6-chloro-4-[3-(pyridin-2-ylcarbonylamino)phenyl]-<br>
quinazoline("A21"),<br>
2-amino-6-chloro-4-[3-(pyridin-4-ylcarbonylamino)phenyl]-<br>
quinazoline ("A22"),<br>
2-amino-6-chloro-4-[3-(pyridin-3-ylcarbonylamino)phenyl]-<br>
quinazoline ("A23"),<br>
2-amino-6-chloro-4-[3-(4-methoxycarbonylbenzoylamino)-<br>
phenyl]quinazoline ("A28"),<br>
2-amino-6-chloro-4-[3-(3-fluorobenzoylamino)phenyl]quinazoline<br>
("A29"),<br><br>
-85-<br>
2-amino-6-chloro-4-[3-(4-fluorobenzoylamino)phenyl]quinazoline<br>
("A30"),<br>
2-amino-6-chloro-4-[3-(2-chlorobenzoylamino)phenyl]quinazo-<br>
line("A31"),<br>
2-amino-6-chloro-4-(3-benzoylaminophenyl)quinazoline ("A32"),<br>
2-amino-6-chloro-4-[3-(3-aminocarbonylpropionylamino)phenyl]-<br>
quinazoline ("A3"),<br>
2-amino-6-chloro-4-[3-(indol-7-ylcarbonylamino)phenyl]quinazo-<br>
line("A11"),<br>
2-amino-6-chloro-4-(3-{3-[(tert-butyloxycarbonyl)amino]-<br>
propionylamino}phenyl)quinazoline ("A12"),<br>
2-amino-6-chloro-4-(3-{4-[(tert-butyloxycarbonyl)amino]butyryl-<br>
amino}phenyl)quinazoline ("A14"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-<br>
propionylamino}phenyl)quinazoline ("A24"),<br>
(R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-<br>
propionylamino}phenyl)quinazoline ("A26"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-<br>
(tert-butoxy)propionylamino}phenyl)quinazoline ("A32"),<br>
(R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-<br>
(tert-butoxy)propionylamino}phenyl)quinazoline ("A32a"),<br>
(2S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-<br>
(tert-butoxy)butyrylamino}phenyl)quinazoline ("A34"),<br>
(2R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-<br>
(tert-butoxy)butyrylamino}phenyl)quinazoline ("A34a"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-<br>
aminocarbonylpropionylamino}phenyl)quinazoline ("A36"),<br>
(R)-2-amino-6-chloro-4-(3-{2-[(tert-butyloxycarbonyl)amino]-3-<br>
aminocarbonylpropionylamino}phenyl)quinazoline ("A38"),<br>
(S)-2-amino-6-chloro-4-(3-{2-[(tert-butyioxycarbonyl)amino]-3-<br>
(1 H-imidazol-4-yl)propionylamino}phenyl)quinazGline ("A40"),<br><br>
-86-<br>
2-amino-6-chloro-4-[3-(indazol-7-ylcarbonylamino)phenyl]quina-<br>
zoline ("A42"),<br>
2-amino-6-chloro-4-[3-(2-hydroxypyridin-4-ylcarbonylamino)-<br>
phenyl]quinazoline ("A43"),<br>
2-amino-6-chloro-4-[2-(indazol-7-ylcarbonylamino)phenyl]quina-<br>
zoline ("A42a"),<br>
2-amino-6-chloro-4-[2-(2-hydroxypyridin-4-ylcarbonylamino)-<br>
phenyl]quinazoline ("A43a"),<br>
2-amino-6-chloro-4-[3-(3-aminopropionylamino)phenyl]quinazo-<br>
line("A13"),<br>
2-amino-6-chloro-4-[3-(4-aminobutyrylamino)phenyl]quinazoline<br>
("A15"),<br>
(S)-2-amino-6-chloro-4-[3-(2-aminopropionylamino)phenyl]quin-<br>
azoline ("A25"),<br>
(R)-2-amino-6-chloro-4-[3-(2-aminopropionylamino)phenyl]quin-<br>
azoline ("A27"),<br>
(S)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxypropionylamino)-<br>
phenyl]quinazoline ("A33"),<br>
(R)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxypropionylamino)-<br>
phenyljquinazoline ("A33a"),<br>
(2S)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxybutyrylamino)-<br>
phenyl]quinazoline ("A35"),<br>
(2R)-2-amino-6-chloro-4-[3-(2-amino-3-hydroxybutyrylamino)-<br>
phenyl]quinazoline ("A35a"),<br>
(S)-2-amino-6-chloro-4-[3-(2-amino-3-aminocarbonylpropionyl-<br>
amino)phenyl]quinazoline ("A37"),<br>
(R)-2-amino-6-chloro-4-[3-(2-amino-3-aminocarbonylpropionyl-<br>
amino)phenyl]quinazoline ("A39"),<br>
(R)-2-amino-6-ch!oro-4-[3-(2-amino-3-(1/-/-imidazol-4-yl)-<br>
propionylamino)phenyl]quinazoline ("A41"),<br>
2-amino-6-chloro-4-[5-fluoro-4-methoxy-2-benzoylaminophenyl]-<br>
quinazoline ("A44"),<br><br>
-87-<br>
2-amino-6-chloro-4-(4-chloro-3-{2-[(tert-butyloxycarbonyl)-<br>
amino]-2-(1/-y-imidazol-4-yl)acetamido}phenyl)quinazoline ("A45"),<br>
2-amino-6-chloro-4-{4-chloro-3-[2-amino-2-(1/-/-imidazol-4-yl)-<br>
acetamido]phenyl}quinazoline ("A46"),<br>
2-amino-6-chloro-4-{4-chloro-2-[2-amino-2-(1H-imidazol-4-yl)-<br>
acetamido]phenyl}quinazoline ("A47"),<br>
4-{3-[3-(2-amino-7-methylquinazolin-4-yl)-5-chlorophenyl]-<br>
ureido}benzoic acid ("A48"),<br>
4-{3-[2-(2-amino-7-methylquinazolin-4-yl)-5-chlorophenyl]-<br>
ureido}benzoic acid ("A49"),<br>
2-amino-6-methoxy-4-[4-methoxy-3-(3-fluorophenylsulfon-<br>
amido)phenyl]quinazoline ("A50"),<br>
2-amino-6-methoxy-4-[4-methoxy-2-(3-fluorophenylsulfon-<br>
amido)phenyl]quinazoline ("A51"),<br>
2-amino-6-chloro-4-[3-(3-trifluoromethylbenzyloxy)phenyl]quina-<br>
zoline ("A56"),<br>
2-amino-6-chloro-4-[2-(3-trifluoromethylbenzyloxy)phenyl]quina-<br>
zoline ("A57"),<br>
2-amino-6-aminocarbonylmethoxy-4-(4-methoxy-3-acetamido-<br>
phenyl)quinazoline ("A52"),<br>
2-amino-6-aminocarbonylmethoxy-4-(4-methoxy-2-acetamido-<br>
phenyl)quinazoline ("A53"),<br>
2-amino-4-[4-ethoxy-3-(2-hydroxyethoxy)phenyl]-6-[2-(4-methyl-<br>
piperazin-1 -yl)ethoxy]quinazoline ("A54"),<br>
2-amino-4-[4-ethoxy-2-(2-hydroxyethoxy)phenyl]-6-[2-(4-methyl-<br>
piperazin-1-yl)ethoxy]quinazoline ("A55"),<br>
2-amino-6-chloro-4-[3-(3-methoxycarbonylpropoxy)-4-methoxy-<br>
phenyi]quinazoline,<br>
2-amino-6-chloro-4-[3-(3-carboxypropoxy)-4-methoxyphenyl]-<br>
quinazoline ("A58"),<br>
2-amino-6-chloro-4-[2-(3-carboxypropoxy)-4-methoxyphenyl]-<br>
quinazoline ("A59").<br><br>
-88-<br>
2-amino-6-chloro-4-[3-(3-carboxypropoxy)-5-methoxyphenyl]-<br>
quinazoline ("A66"),<br>
2-amino-6-chloro-4-[2-(3-carboxypropoxy)-5-methoxyphenyl]-<br>
quinazoline ("A67"),<br>
2-amino-6-aminomethylcarbonylamino-4-[3-(3-aminocarbonyl-<br>
propoxy)phenyl]quinazoline ("A60"),<br>
2-amino-6-aminomethylcarbonylamino-4-[2-(3-aminocarbonyl-<br>
propoxy)phenyl]quinazoline ("A61"),<br>
2-amino-6-chloro-4-{3-[2-(tert-butyloxycarbonylamino)ethoxy]-<br>
phenyl}quinazoline,<br>
2-amino-6-chloro-4-[3-(2-aminoethoxy)phenyl]quinazoline,<br>
2-amino-6-chloro-4-(3-{2-[3-(2-fluorophenyl)ureido]ethoxy}-<br>
phenyl)quinoline ("A62"),<br>
2-amino-7-methoxy-4-[3-(2-hydroxyethoxy)phenyl]quinazoline,<br>
2-amino-7-methoxy-4-{3-[2-(2-carbamoylethoxy)ethoxy]phenyl]-<br>
quinazoline ("A63"),<br>
methyl {[3-(2-aminoquinazolin-4-yl)-2,4-dichlorophenylcar-<br>
bamoyl]methoxy}acetate,<br>
{[3-(2-aminoquinazolin-4-yl)-2,4-dichlorophenylcarbamoyl]-<br>
methoxy}acetic acid ("A64"),<br>
{[2-(2-aminoquinazolin-4-yl)-4-chlorophenylcarbamoyl]methoxy}-<br>
acetic acid ("A65"),<br>
2-{2-[3-(2-amino-6-chloroquinazolin-4-yl)phenoxy]acetylamino-3-<br>
phenylpropionic acid ("A68"),<br>
2-{2-[2-(2-amino-6-chloroquinazolin-4-yl)-5,6-dichlorophenoxy]-<br>
acetylamino-3-phenylpropionic acid ("A69"),<br>
2-amino-6-fluoro-4-[3-(4-methylpiperazin-1-yl)phenyl]quinazoline<br>
("A70"),<br>
2-amino-6-fluoro-4-[2-(4-methylpiperazin-1-yl)-6-fluorophenyl]-<br>
quinazoline("A71"),<br>
2-amino-6-fluoro-4-[3-(1/-/-indol-7-ylaminocarbonyl)-4-methoxy-<br>
phenyl]quinazoline ("A72"),<br><br>
-89-<br>
2-amino-6-fluoro-4-[2-(1H-indol-7-ylaminocarbonyl)-4-methoxy-<br>
phenyl]quinazoline ("A73"),<br>
2-amino-6-chloro-4-(3-aminophenyl)quinazoline ("6"),<br>
2-amino-6-chloro-4-(3-hydroxyphenyl)quinazoline,<br>
and pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios.<br>
16.	Process for the preparation of compounds of the formula I according<br>
to Claims'!-15 and pharmaceutically usable derivatives, solvates,<br>
salts, tautomers and stereoisomers thereof, characterised in that one<br>
or more radical(s) R1, R2, R3, R4 and/or R5 in a compound of the for-<br>
mula I is (are) converted into one or more radical(s) R1, R2, R3, R4<br>
and/or R5<br>
by alkylating or acylating a hydroxyl and/or amino group group,<br>
and/or a base or acid of the formula I is converted into one of its<br>
salts.<br>
17.	Medicaments comprising at least one compound of the formula I<br>
and/or pharmaceutically usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios,<br>
and optionally excipients and/or adjuvants.<br>
18.	Use of compounds of the formula I and pharmaceutically usable<br>
derivatives, salts, solvates, tautomers and stereoisomers thereof,<br>
including mixtures thereof in all ratios, for the preparation of a medi-<br>
cament for the treatment and/or prophylaxis of diseases in which the<br>
inhibition, regulation and/or modulation of HSP90 plays a role.<br>
19.	Use according to Claim 18 of compounds of the formula I and phar-<br>
maceutically usable derivatives, salts, solvates, tautomers and<br><br>
-90-<br>
stereoisomers thereof, including mixtures thereof in all ratios, for the<br>
preparation of a medicament for the treatment or prevention of<br>
tumour diseases, viral diseases, for immune suppression in trans-<br>
plants, inflammation-induced diseases, cystic fibrosis, diseases<br>
associated with angiogenesis, infectious diseases, autoimmune dis-<br>
eases, ischaemia, fibrogenetic diseases,<br>
for the promotion of nerve regeneration,<br>
for inhibiting the growth of cancer, tumour cells and tumour metasta-<br>
ses,<br>
for the protection of normal cells against toxicity caused by chemo-<br>
therapy,<br>
for the treatment of diseases in which incorrect protein folding or<br>
aggregation is a principal causal factor.<br>
20. Use according to Claim 18, where the tumour diseases are fibro-<br>
sarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic<br>
sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangio-<br>
sarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma,<br>
Ewing's tumour, leiosarcoma, rhabdomyosarcoma, colon carcinoma,<br>
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer,<br>
squamous cell carcinoma, basal cell carcinoma, adenocarcinoma,<br>
syringocarcinoma, sebaceous gland carcinoma, papillary carcinoma,<br>
papillary adenocarcinomas, cystadenocarcinomas, bone marrow car-<br>
cinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,<br>
bile duct carcinoma, choriocarcinoma, seminoma, embryonic carci-<br>
noma, Wilm's tumour, cervical cancer, testicular tumour, lung carci-<br>
noma, small-cell lung carcinoma, bladder carcinoma, epithelial carci-<br>
noma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,<br>
ependymoma, pinealoma, haemangioblastoma, acoustic neuroma,<br>
oligodendroglioma, meningioma, melanoma, neuroblastoma, retino-<br>
blastoma, leukaemia, lymphoma, multiple myeloma, Waldenstrom's<br>
macroglobulinaemia and heavy chain disease.<br><br>
-91 -<br>
21.	Use according to Claim 19, where the viral pathogen of the viral dis-<br>
eases is selected from the group consisting of hepatitis type A, hepa-<br>
titis type B, hepatitis type C, influenza, varicella, adenovirus, herpes<br>
simplex type I (HSV-I), herpes simplex type II (HSV-II), cattle plague,<br>
rhinovirus, echovirus, rotavirus, respiratory syncytial virus (RSV),<br>
papillomavirus, papovavirus, cytomegalovirus, echinovirus, arbovirus,<br>
huntavirus, Coxsackie virus, mumps virus, measles virus, rubella<br>
virus, polio virus, human immunodeficiency virus type I (HIV-I) and<br>
human immunodeficiency virus type II (HIV-II).<br>
22.	Use according to Claim 19, where the inflammation-induced diseases<br>
are rheumatoid arthritis, asthma, multiple sclerosis, type 1 diabetes,<br>
lupus erythematosus, psoriasis and inflammatory bowel disease.<br>
23.	Use according to Claim 19, where the diseases associated with<br>
angiogenesis are diabetic retinopathy, haemangiomas, endometriosis<br>
and tumour angiogenesis.<br>
24.	Use according to Claim 19, where the fibrogenetic diseases are<br>
sclerorma, polymyositis, systemic lupus, cirrhosis of the liver, keloid<br>
formation, interstitial nephritis and pulmonary fibrosis.<br>
25.	Use according to Claim 18, where the diseases in which incorrect<br>
protein folding or aggregation is a principal causal factor are scrapie,<br>
Creutzfeldt-Jakob disease, Huntington's or Alzheimer's.<br>
26.	Medicaments comprising at least one compound of the formula I<br>
and/or pharmaceutical usable derivatives, salts, solvates, tautomers<br>
and stereoisomers thereof, including mixtures thereof in all ratios,<br>
and at least one further medicament active ingredient.<br><br>
-92-<br>
27. Set (kit) consisting of separate packs of<br>
(a)	an effective amount of a compound of the formula I and/or<br>
pharmaceutically usable derivatives, salts, solvates, tautomers and<br>
stereoisomers thereof, including mixtures thereof in all ratios,<br>
and<br>
(b)	an effective amount of a further medicament active ingredi-<br>
ent.<br><br>
Novel phenylquinazoline derivatives of the formula I<br><br>
in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1,<br>
are HSP90 inhibitors and can be used for the preparation of a medicament<br>
for the treatment of diseases in which the inhibition, regulation and/or<br>
modulation of HSP90 plays a role.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDQ4Mzcta29sbnAtMjAwNy10cmFuc2xhdGVkIGNvcHkgb2YgcHJpb3JpdHkgZG9jdW1lbnQucGRm" target="_blank" style="word-wrap:break-word;">04837-kolnp-2007-translated copy of priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1LT0xOUC0yMDA3LSgwOS0wMS0yMDEzKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">4837-KOLNP-2007-(09-01-2013)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUNBTkNFTExFRCBQQUdFUy5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-CANCELLED PAGES.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtRk9STSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtRk9STSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtTEVUVEVSIFBBVEVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-LETTER PATENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi1DT01QTEVURS5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-GRANTED-SPECIFICATION-COMPLETE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUlOVEVSTkFUSU9OQUwgUFVCTElDQVRJT04ucGRm" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-INTERNATIONAL PUBLICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LUlOVEVSTkFUSU9OQUwgU0VBUkNIIFJFUE9SVCAmIE9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-INTERNATIONAL SEARCH REPORT &amp; OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDgzNy1rb2xucC0yMDA3LVRSQU5TTEFURUQgQ09QWSBPRiBQUklPUklUWSBET0NVTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">4837-kolnp-2007-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDQ4Mzcta29sbnAtMjAwNy5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-04837-kolnp-2007.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="258802-polypeptide-comprising-an-amino-acid-sequence-and-conjugate-comprising-said-polypeptide.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="258804-method-and-quench-apparatus-for-melt-spinning-of-continuous-polymeric-filament-yarns.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>258803</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>4837/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>07/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>14-Feb-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>07-Feb-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>12-Dec-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>MERCK PATENT GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>FRANKFURTER STRASSE 250 64293 DARMSTADT</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>WOLE, MICHAEL</td>
											<td>NUSSBAUMALLEE 59 64297 DARMSTADT</td>
										</tr>
										<tr>
											<td>2</td>
											<td>EGGENWEILER, HANS-MICHAEL</td>
											<td>KAFKASTRASSE 4, 64291 DARMSTADT</td>
										</tr>
										<tr>
											<td>3</td>
											<td>BUCHSTALLER, HANS-PETER</td>
											<td>NECKARSTRASSE 6, 64347 GRIESHEIM</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 239/84</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2006/003734</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-04-24</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>102005022977.8</td>
									<td>2005-05-19</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/258803-phenylquinazoline-derivatives by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 04:22:56 GMT -->
</html>
